[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fE7RrXe6HZ5fOg2q-2u8L0jUf9VmcBckcqz8juj_t7LY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Virginia Commonwealth University",[4],636,false,97,28,22832037,42,442,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Obesity",22,{"name":18,"count":19},"Breast Cancer",20,{"name":21,"count":22},"Leukemia",12,{"name":24,"count":25},"Pediatric Obesity",9,{"name":27,"count":25},"Stress",{"name":29,"count":25},"Heart Failure",{"name":31,"count":25},"Lymphoma",{"name":33,"count":25},"Traumatic Brain Injury",[35,40,45,50,55,59,64,69,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02957968","Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","2022-08-04","Doxorubicin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04502602","Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer","2024-10-30","Neratinib 160 mg",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05424003","Randomized Double Blinded Placebo-Controlled w\u002FSemaglutide to Prevent Weight Gain After Liver Transplant","2026-02","Semaglutide Pen Injector",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06771323","Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia","2026-05","Valbenazine",{"nctId":56,"briefTitle":57,"date":53,"intervention":58},"NCT06688825","Feasibility Study for the Comprehensive Overweight\u002FObesity Management Pre-Kidney Transplant (COMPKT) Program","Blood draw",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06874192","Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study","2026-05-30","Low-dose colchicine at 0.5mg daily",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05886582","Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","2026-06","Rotigotine Transdermal System [Neupro]",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT06062966","The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)","Anakinra",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06001320","De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients","2026-09-01","Letermovir 480 mg once daily",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06362226","Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management","2026-11","Steroid\u002FAntibiotic",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,119,146,169,317,373,407,429,462,494,515,543,564,591,609,629,654,678,696,723,741,767,795,820,848,871,901,919,937,955,973,991,1009,1027,1052,1077,1097,1122,1140,1162,1180,1205,1224,1263,1302,1326,1352,1370,1394,1418,1442,1468,1494,1521,1539,1562,1588,1606,1629,1653,1671,1689,1707,1725,1743,1768,1786,1812,1838,1864,1889,1911,1929,1947,1965,1983,2008,2034,2052,2098,2128,2172,2197,2221,2246,2264,2290,2308,2331,2355,2382,2400,2418,2442,2466,2491,2515,2541,2559,2577,2595,2613,2636,2679,2732,2774,2800,2848,2886,2915,2937,2967,3001,3035,3068,3101,3133,3151,3169,3187,3205,3223,3241,3265,3290,3318,3336,3354,3372,3390,3415,3438,3461,3485,3511,3529,3547,3565,3588,3606,3632,3650,3674,3699,3722,3748,3772,3795,3817,3842,3864,3890,3908,3933,3951,3969,3991,4009,4027,4050,4076,4100,4122,4144,4169,4192,4217,4235,4253,4279,4304,4341,4377,4414,4432,4450,4478,4506,4524,4547,4583,4601,4619,4637,4655,4673,4698,4716,4734,4759,4781,4806,4824,4842,4860,4884,4923,4949,4967,4985,5003,5030,5048,5084,5102,5120,5138,5156,5182,5200,5218,5240,5258,5284,5307,5325,5350,5384,5410,5434,5452,5474,5496,5518,5536,5559,5584,5602,5627,5652,5670,5707,5736,5762,5780,5798,5816,5842,5864,5887,5913,5931,5953,5974,5999,6023,6045,6071,6089,6114,6137,6160,6185,6203,6221],{"intervention":92,"totalTrials":93,"cells":94},"Oral Azacitidine",1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":117},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":22,"conditions":114,"interventions":116},"NCT06370000","Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality","RECRUITING",[88],"2027-01-31","2029-01-31","2024-11-07",[115],"Acute Myeloid Leukemia",[92],{"trials":118,"activeCount":97},[],{"intervention":120,"totalTrials":93,"cells":121},"Galantamine HBr extended-release 8mg capsules (8mg ER).",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":144},{"trials":123,"activeCount":97},[],{"trials":125,"activeCount":97},[],{"trials":127,"activeCount":97},[],{"trials":129,"activeCount":97},[],{"trials":131,"activeCount":93,"soonestReadout":136},[132],{"nctId":133,"briefTitle":134,"status":109,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":143},"NCT07284290","Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia",[88],"2029-11","2025-12-08",120,[140,141,142],"Dementia With Lewy Bodies","Parkinson Disease Dementia","Healthy Controls",[120],{"trials":145,"activeCount":97},[],{"intervention":77,"totalTrials":93,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":165,"NA":167},{"trials":149,"activeCount":97},[],{"trials":151,"activeCount":97},[],{"trials":153,"activeCount":97},[],{"trials":155,"activeCount":93,"soonestReadout":76},[156],{"nctId":74,"briefTitle":75,"status":157,"phases":158,"primaryCompletion":76,"completion":76,"start":159,"enrollment":160,"conditions":161,"interventions":164},"ACTIVE_NOT_RECRUITING",[87],"2023-09-25",30,[162,163],"Kidney Transplant; Complications","CMV",[77],{"trials":166,"activeCount":97},[],{"trials":168,"activeCount":97},[],{"intervention":72,"totalTrials":170,"cells":171},14,{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":192,"PHASE3":277,"PHASE4":305,"NA":307},{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":93,"soonestReadout":67},[176,187],{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT03057028","Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension","COMPLETED",[85],"2018-06-07","2016-04",7,[185],"Pulmonary Arterial Hypertension",[72],{"nctId":70,"briefTitle":71,"status":109,"phases":188,"primaryCompletion":67,"completion":67,"start":189,"enrollment":19,"conditions":190,"interventions":191},[85],"2024-02-05",[29],[72],{"trials":193,"activeCount":93,"soonestReadout":198},[194,204,216,225,236,246,256,266],{"nctId":195,"briefTitle":196,"status":157,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":203},"NCT05177822","Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure",[86],"2027-02-22","2027-12-30","2022-05-24",84,[29],[72],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":97,"conditions":211,"interventions":215},"NCT03062176","Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease","WITHDRAWN",[86],"2019-05-15","2017-04-03",[212,213,214],"Heart Failure, Systolic","Renal Disease, End Stage","Chronic Kidney Diseases",[72],{"nctId":217,"briefTitle":218,"status":179,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT01300650","Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure",[85,86],"2011-08","2011-02",11,[29],[72],{"nctId":226,"briefTitle":227,"status":228,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT03224585","Treatment of Acute Pericarditis With Anakinra","TERMINATED",[86],"2020-02-01","2018-05-11",5,[234],"Acute Pericarditis",[72],{"nctId":237,"briefTitle":238,"status":179,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":160,"conditions":243,"interventions":245},"NCT01175018","Anakinra to Prevent Adverse Post-infarction Remodeling (2)",[86],"2012-09","2012-12","2010-07",[244,29],"Acute Myocardial Infarction",[72],{"nctId":247,"briefTitle":248,"status":179,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":255},"NCT04017936","Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis",[86],"2024-06-30","2020-10-23",17,[254],"Cardiac Sarcoidosis",[72],{"nctId":257,"briefTitle":258,"status":179,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT03797001","Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2",[86],"2024-07-22","2019-01-04",102,[212,264],"Inflammation",[72],{"nctId":267,"briefTitle":268,"status":179,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT02173548","Interleukin-1 Blockade in HF With Preserved EF",[86],"2017-04-11","2017-06-01","2014-09",31,[275],"Heart Failure With Normal Ejection Fraction",[72],{"trials":278,"activeCount":97},[279,288,298],{"nctId":280,"briefTitle":281,"status":179,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT01936909","Interleukin-1 Blockade in Recently Decompensated Heart Failure",[86,87],"2016-09-23","2014-02",60,[29],[72,72],{"nctId":289,"briefTitle":290,"status":179,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT00789724","Anakinra to Prevent Post-infarction Remodeling",[87],"2009-08","2008-11",10,[296],"ST Segment Elevation Acute Myocardial Infarction",[72],{"nctId":299,"briefTitle":300,"status":179,"phases":301,"primaryCompletion":302,"completion":302,"start":284,"enrollment":160,"conditions":303,"interventions":304},"NCT01936844","Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)",[86,87],"2015-05",[29],[72,72],{"trials":306,"activeCount":97},[],{"trials":308,"activeCount":97},[309],{"nctId":310,"briefTitle":311,"status":179,"phases":312,"primaryCompletion":313,"completion":313,"start":314,"enrollment":22,"conditions":315,"interventions":316},"NCT01542502","Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction",[89],"2013-06","2012-02",[29],[72],{"intervention":318,"totalTrials":319,"cells":320},"Cyclophosphamide",2,{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":351,"PHASE4":369,"NA":371},{"trials":322,"activeCount":97},[],{"trials":324,"activeCount":97},[],{"trials":326,"activeCount":93,"soonestReadout":38},[327],{"nctId":36,"briefTitle":37,"status":157,"phases":328,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":346},[86],"2027-03-31","2017-01-24",46,[333,334,335,336,337,338,339,340,341,342,343,344,345],"Breast Adenocarcinoma","Estrogen Receptor- Negative Breast Cancer","Estrogen Receptor-positive Breast Cancer","HER2\u002FNeu Negative","Invasive Breast Carcinoma","Progesterone Receptor Negative","Progesterone Receptor Positive Tumor","Stage II Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Triple-negative Breast Carcinoma",[39,318,347,348,349,350],"Paclitaxel","Carboplatin","Decitabine","Pembrolizumab",{"trials":352,"activeCount":97},[353],{"nctId":354,"briefTitle":355,"status":179,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT00003187","Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma",[86,87],"2005-02","1995-05",19,[21,31,361],"Myelodysplastic Syndromes",[363,364,365,366,367,368],"filgrastim","cyclophosphamide","cyclosporine","cytarabine","methotrexate","methylprednisolone",{"trials":370,"activeCount":97},[],{"trials":372,"activeCount":97},[],{"intervention":347,"totalTrials":319,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":395,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[379],{"nctId":380,"briefTitle":381,"status":207,"phases":382,"primaryCompletion":383,"completion":383,"start":384,"enrollment":97,"conditions":385,"interventions":393},"NCT02059967","Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC",[85],"2015-01","2014-03",[386,387,388,389,390,391,392],"Adenocarcinoma of the Lung","Large Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[347,394],"carboplatin",{"trials":396,"activeCount":93,"soonestReadout":38},[397],{"nctId":36,"briefTitle":37,"status":157,"phases":398,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":399,"interventions":400},[86],[333,334,335,336,337,338,339,340,341,342,343,344,345],[39,318,347,348,349,350],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":97},[],{"trials":406,"activeCount":97},[],{"intervention":394,"totalTrials":319,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":417,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":410,"activeCount":97},[],{"trials":412,"activeCount":97},[413],{"nctId":380,"briefTitle":381,"status":207,"phases":414,"primaryCompletion":383,"completion":383,"start":384,"enrollment":97,"conditions":415,"interventions":416},[85],[386,387,388,389,390,391,392],[347,394],{"trials":418,"activeCount":93,"soonestReadout":38},[419],{"nctId":36,"briefTitle":37,"status":157,"phases":420,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":421,"interventions":422},[86],[333,334,335,336,337,338,339,340,341,342,343,344,345],[39,318,347,348,349,350],{"trials":424,"activeCount":97},[],{"trials":426,"activeCount":97},[],{"trials":428,"activeCount":97},[],{"intervention":39,"totalTrials":319,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":450,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":432,"activeCount":97},[],{"trials":434,"activeCount":97},[435],{"nctId":436,"briefTitle":437,"status":179,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":448},"NCT01375699","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",[85],"2017-08-04","2018-01-19","2011-08-11",26,[18,444,445,446,447],"Gastrointestinal Cancer","Genitourinary Cancer","Sarcoma","Gynecologic Cancer",[39,449],"Sildenafil",{"trials":451,"activeCount":93,"soonestReadout":38},[452],{"nctId":36,"briefTitle":37,"status":157,"phases":453,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":454,"interventions":455},[86],[333,334,335,336,337,338,339,340,341,342,343,344,345],[39,318,347,348,349,350],{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"intervention":350,"totalTrials":319,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":93,"soonestReadout":38},[470,484],{"nctId":471,"briefTitle":472,"status":228,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":482},"NCT05263492","Study of Lenvatinib w\u002F Pembro in Black Participants w\u002FMismatch Repair-Prof Recurrent Endometrial Cancer",[86],"2024-09-13","2024-10-19","2022-04-01",4,[479,480,481],"Endometrial Cancer","Mismatch Repair-Proficient","Recurrent Endometrial Cancer",[483,350],"Lenvatinib",{"nctId":36,"briefTitle":37,"status":157,"phases":485,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":486,"interventions":487},[86],[333,334,335,336,337,338,339,340,341,342,343,344,345],[39,318,347,348,349,350],{"trials":489,"activeCount":97},[],{"trials":491,"activeCount":97},[],{"trials":493,"activeCount":97},[],{"intervention":49,"totalTrials":93,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":497,"activeCount":97},[],{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":93,"soonestReadout":48},[502],{"nctId":46,"briefTitle":47,"status":109,"phases":503,"primaryCompletion":48,"completion":48,"start":504,"enrollment":505,"conditions":506,"interventions":508},[86],"2024-02-22",50,[507],"NAFLD",[49],{"trials":510,"activeCount":97},[],{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"intervention":516,"totalTrials":93,"cells":517},"Lemborexant 10 MG",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":519,"activeCount":97},[],{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":93,"soonestReadout":528},[524],{"nctId":525,"briefTitle":526,"status":109,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":536},"NCT06981195","Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects",[86],"2029-07-30","2025-05-27",100,[532,533,534,535],"Opioid Use Disorder","Opioid Use","Insomnia","Orexin Antagonist",[516],{"trials":538,"activeCount":97},[],{"trials":540,"activeCount":97},[],{"trials":542,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":546,"activeCount":97},[],{"trials":548,"activeCount":97},[],{"trials":550,"activeCount":93,"soonestReadout":67},[551],{"nctId":65,"briefTitle":66,"status":109,"phases":552,"primaryCompletion":67,"completion":67,"start":553,"enrollment":554,"conditions":555,"interventions":557},[86],"2023-09-11",40,[556],"Substance-Related Disorders",[68],{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[],{"intervention":565,"totalTrials":93,"cells":566},"Neratinib",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":93,"soonestReadout":577},[573],{"nctId":574,"briefTitle":575,"status":109,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":583},"NCT03919292","Neratinib + Valproate in Advanced Solid Tumors, w\u002FExpansion Cohort in Ras-Mutated Ca",[85,86],"2029-12-31","2031-01-31","2019-05-01",83,[582],"Solid Tumor, Adult",[565,584],"Divalproex Sodium",{"trials":586,"activeCount":97},[],{"trials":588,"activeCount":97},[],{"trials":590,"activeCount":97},[],{"intervention":584,"totalTrials":93,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":594,"activeCount":97},[],{"trials":596,"activeCount":97},[],{"trials":598,"activeCount":93,"soonestReadout":577},[599],{"nctId":574,"briefTitle":575,"status":109,"phases":600,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":601,"interventions":602},[85,86],[582],[565,584],{"trials":604,"activeCount":97},[],{"trials":606,"activeCount":97},[],{"trials":608,"activeCount":97},[],{"intervention":54,"totalTrials":93,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":612,"activeCount":97},[],{"trials":614,"activeCount":97},[],{"trials":616,"activeCount":93,"soonestReadout":53},[617],{"nctId":51,"briefTitle":52,"status":109,"phases":618,"primaryCompletion":53,"completion":53,"start":619,"enrollment":19,"conditions":620,"interventions":622},[86],"2024-12-17",[621],"Cervical Dystonia",[54],{"trials":624,"activeCount":97},[],{"trials":626,"activeCount":97},[],{"trials":628,"activeCount":97},[],{"intervention":630,"totalTrials":93,"cells":631},"Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":633,"activeCount":97},[],{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":93,"soonestReadout":642},[638],{"nctId":639,"briefTitle":640,"status":109,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":8,"conditions":644,"interventions":647},"NCT06728072","Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer",[86],"2035-07-01","2025-03-07",[645,646],"Colorectal Cancer","CRC",[630],{"trials":649,"activeCount":97},[],{"trials":651,"activeCount":97},[],{"trials":653,"activeCount":97},[],{"intervention":655,"totalTrials":93,"cells":656},"Accelerated partial breast irradiation",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":658,"activeCount":97},[],{"trials":660,"activeCount":97},[],{"trials":662,"activeCount":93,"soonestReadout":578},[663],{"nctId":664,"briefTitle":665,"status":109,"phases":666,"primaryCompletion":578,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT06185205","ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy",[86],"2033-01-31","2023-12-12",170,[18],[655],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":97},[],{"trials":677,"activeCount":97},[],{"intervention":349,"totalTrials":93,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":681,"activeCount":97},[],{"trials":683,"activeCount":97},[],{"trials":685,"activeCount":93,"soonestReadout":38},[686],{"nctId":36,"briefTitle":37,"status":157,"phases":687,"primaryCompletion":38,"completion":329,"start":330,"enrollment":331,"conditions":688,"interventions":689},[86],[333,334,335,336,337,338,339,340,341,342,343,344,345],[39,318,347,348,349,350],{"trials":691,"activeCount":97},[],{"trials":693,"activeCount":97},[],{"trials":695,"activeCount":97},[],{"intervention":697,"totalTrials":93,"cells":698},"Sacubitril-valsartan",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":700,"activeCount":97},[],{"trials":702,"activeCount":97},[],{"trials":704,"activeCount":93,"soonestReadout":709},[705],{"nctId":706,"briefTitle":707,"status":109,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":715},"NCT05194111","Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril\u002FValsartan",[85,86],"2027-11-30","2028-11-30","2022-08-11",53,[29,714],"Heart Dysfunction",[697,716],"Valsartan",{"trials":718,"activeCount":97},[],{"trials":720,"activeCount":97},[],{"trials":722,"activeCount":97},[],{"intervention":716,"totalTrials":93,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":726,"activeCount":97},[],{"trials":728,"activeCount":97},[],{"trials":730,"activeCount":93,"soonestReadout":709},[731],{"nctId":706,"briefTitle":707,"status":109,"phases":732,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":733,"interventions":734},[85,86],[29,714],[697,716],{"trials":736,"activeCount":97},[],{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"intervention":742,"totalTrials":93,"cells":743},"Zanubrutinib",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":745,"activeCount":97},[],{"trials":747,"activeCount":97},[],{"trials":749,"activeCount":93,"soonestReadout":754},[750],{"nctId":751,"briefTitle":752,"status":109,"phases":753,"primaryCompletion":754,"completion":755,"start":529,"enrollment":756,"conditions":757,"interventions":760},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[86],"2029-07-31","2032-07-31",21,[758,759],"Diffuse Large B-cell Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma",[742],{"trials":762,"activeCount":97},[],{"trials":764,"activeCount":97},[],{"trials":766,"activeCount":97},[],{"intervention":768,"totalTrials":93,"cells":769},"Intestinal Microbiota Transplant (IMT)",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":771,"activeCount":97},[],{"trials":773,"activeCount":97},[],{"trials":775,"activeCount":93,"soonestReadout":780},[776],{"nctId":777,"briefTitle":778,"status":109,"phases":779,"primaryCompletion":780,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":788},"NCT05548452","Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease",[85,86],"2026-11-30","2026-12-30","2022-11-21",80,[785,786,787],"Liver Disease; Alcohol-Related","Cirrhosis","Alcohol Use Disorder",[768],{"trials":790,"activeCount":97},[],{"trials":792,"activeCount":97},[],{"trials":794,"activeCount":97},[],{"intervention":796,"totalTrials":93,"cells":797},"Chemotherapy",{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":799,"activeCount":97},[],{"trials":801,"activeCount":97},[],{"trials":803,"activeCount":93,"soonestReadout":808},[804],{"nctId":805,"briefTitle":806,"status":109,"phases":807,"primaryCompletion":808,"completion":667,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT04643366","Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer",[86],"2028-01-31","2021-01-28",54,[812],"Rectal Cancer",[796],{"trials":815,"activeCount":97},[],{"trials":817,"activeCount":97},[],{"trials":819,"activeCount":97},[],{"intervention":821,"totalTrials":93,"cells":822},"Reduced Dose of Chemotherapy and Immunotherapy",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":824,"activeCount":97},[],{"trials":826,"activeCount":97},[],{"trials":828,"activeCount":93,"soonestReadout":833},[829],{"nctId":830,"briefTitle":831,"status":109,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":554,"conditions":836,"interventions":841},"NCT06731413","Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w\u002FAdv \u003C50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)",[86],"2030-07-30","2033-07-30","2025-02-11",[837,838,839,840],"Non-Small Cell Lung Cancer","NSCLC","Advanced Non-Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer",[821],{"trials":843,"activeCount":97},[],{"trials":845,"activeCount":97},[],{"trials":847,"activeCount":97},[],{"intervention":849,"totalTrials":93,"cells":850},"Azelaic Acid",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":852,"activeCount":97},[],{"trials":854,"activeCount":93,"soonestReadout":780},[855],{"nctId":856,"briefTitle":857,"status":109,"phases":858,"primaryCompletion":780,"completion":780,"start":859,"enrollment":860,"conditions":861,"interventions":862},"NCT06966388","Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation",[85],"2025-08-13",33,[18],[849],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":97},[],{"intervention":44,"totalTrials":93,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":93,"soonestReadout":43},[877],{"nctId":41,"briefTitle":42,"status":157,"phases":878,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":885},[85],"2027-10-31","2020-08-24",18,[883,884],"Advanced Solid Tumor","Ovarian Cancer",[44,886,887,888,889,890,891,892],"Neratinib 200 mg","Neratinib 240 mg","Niraparib 100 mg","Niraparib 200 mg","Niraparib 300 mg","Niraparib at RP2D","Neratinib at RP2D",{"trials":894,"activeCount":97},[],{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":97},[],{"intervention":886,"totalTrials":93,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":93,"soonestReadout":43},[907],{"nctId":41,"briefTitle":42,"status":157,"phases":908,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":909,"interventions":910},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":912,"activeCount":97},[],{"trials":914,"activeCount":97},[],{"trials":916,"activeCount":97},[],{"trials":918,"activeCount":97},[],{"intervention":887,"totalTrials":93,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":97},[],{"trials":924,"activeCount":93,"soonestReadout":43},[925],{"nctId":41,"briefTitle":42,"status":157,"phases":926,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":927,"interventions":928},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[],{"trials":934,"activeCount":97},[],{"trials":936,"activeCount":97},[],{"intervention":888,"totalTrials":93,"cells":938},{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":940,"activeCount":97},[],{"trials":942,"activeCount":93,"soonestReadout":43},[943],{"nctId":41,"briefTitle":42,"status":157,"phases":944,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":945,"interventions":946},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"trials":952,"activeCount":97},[],{"trials":954,"activeCount":97},[],{"intervention":889,"totalTrials":93,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":958,"activeCount":97},[],{"trials":960,"activeCount":93,"soonestReadout":43},[961],{"nctId":41,"briefTitle":42,"status":157,"phases":962,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":963,"interventions":964},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[],{"intervention":890,"totalTrials":93,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":983,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":976,"activeCount":97},[],{"trials":978,"activeCount":93,"soonestReadout":43},[979],{"nctId":41,"briefTitle":42,"status":157,"phases":980,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":981,"interventions":982},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[],{"trials":988,"activeCount":97},[],{"trials":990,"activeCount":97},[],{"intervention":891,"totalTrials":93,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":93,"soonestReadout":43},[997],{"nctId":41,"briefTitle":42,"status":157,"phases":998,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":999,"interventions":1000},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":1002,"activeCount":97},[],{"trials":1004,"activeCount":97},[],{"trials":1006,"activeCount":97},[],{"trials":1008,"activeCount":97},[],{"intervention":892,"totalTrials":93,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1019,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":93,"soonestReadout":43},[1015],{"nctId":41,"briefTitle":42,"status":157,"phases":1016,"primaryCompletion":43,"completion":879,"start":880,"enrollment":881,"conditions":1017,"interventions":1018},[85],[883,884],[44,886,887,888,889,890,891,892],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[],{"trials":1024,"activeCount":97},[],{"trials":1026,"activeCount":97},[],{"intervention":1028,"totalTrials":93,"cells":1029},"Investigational Agent Administration",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":93,"soonestReadout":1038},[1034],{"nctId":1035,"briefTitle":1036,"status":109,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":160,"conditions":1041,"interventions":1043},"NCT06636123","GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy",[85],"2027-04-30","2031-10-31","2025-02-18",[1042],"Castration-resistant Prostate Cancer",[1028],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[],{"trials":1051,"activeCount":97},[],{"intervention":1053,"totalTrials":93,"cells":1054},"VVZ-2471 for 14-day intervention",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1056,"activeCount":97},[],{"trials":1058,"activeCount":93,"soonestReadout":1064},[1059],{"nctId":1060,"briefTitle":1061,"status":1062,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":285,"conditions":1067,"interventions":1068},"NCT07531316","Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers","NOT_YET_RECRUITING",[85],"2031-12-20","2031-12-30","2026-06-01",[142],[1053],{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1080,"activeCount":97},[],{"trials":1082,"activeCount":93,"soonestReadout":62},[1083],{"nctId":60,"briefTitle":61,"status":109,"phases":1084,"primaryCompletion":62,"completion":62,"start":1085,"enrollment":160,"conditions":1086,"interventions":1088},[85],"2025-03-12",[1087],"Statin Adverse Reaction",[63],{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[],{"intervention":1098,"totalTrials":93,"cells":1099},"Arm 1 cemiplimab",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1101,"activeCount":97},[],{"trials":1103,"activeCount":93,"soonestReadout":1108},[1104],{"nctId":1105,"briefTitle":1106,"status":1062,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":19,"conditions":1110,"interventions":1112},"NCT07365839","Cemiplimab +\u002F- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma",[85],"2035-02-28","2026-07-01",[1111],"Hepatocellular Carcinoma",[1098,1113],"Arm 2 cemiplimab and fianlimab",{"trials":1115,"activeCount":97},[],{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[],{"intervention":1113,"totalTrials":93,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1125,"activeCount":97},[],{"trials":1127,"activeCount":93,"soonestReadout":1108},[1128],{"nctId":1105,"briefTitle":1106,"status":1062,"phases":1129,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":19,"conditions":1130,"interventions":1131},[85],[1111],[1098,1113],{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[],{"trials":1139,"activeCount":97},[],{"intervention":82,"totalTrials":93,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1143,"activeCount":97},[],{"trials":1145,"activeCount":93,"soonestReadout":81},[1146],{"nctId":79,"briefTitle":80,"status":1062,"phases":1147,"primaryCompletion":81,"completion":1148,"start":1149,"enrollment":294,"conditions":1150,"interventions":1152},[85],"2027-01","2026-04-28",[1151],"Periorbital Burns",[82,1153],"5-FU\u002FKenalog",{"trials":1155,"activeCount":97},[],{"trials":1157,"activeCount":97},[],{"trials":1159,"activeCount":97},[],{"trials":1161,"activeCount":97},[],{"intervention":1153,"totalTrials":93,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":93,"soonestReadout":81},[1168],{"nctId":79,"briefTitle":80,"status":1062,"phases":1169,"primaryCompletion":81,"completion":1148,"start":1149,"enrollment":294,"conditions":1170,"interventions":1171},[85],[1151],[82,1153],{"trials":1173,"activeCount":97},[],{"trials":1175,"activeCount":97},[],{"trials":1177,"activeCount":97},[],{"trials":1179,"activeCount":97},[],{"intervention":1181,"totalTrials":93,"cells":1182},"Olutasidenib Investigational Agent Administration",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":93,"soonestReadout":1191},[1187],{"nctId":1188,"briefTitle":1189,"status":109,"phases":1190,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1196},"NCT07130695","Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation",[85],"2028-10-31","2030-10-31","2026-02-02",15,[115],[1181],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[],{"trials":1202,"activeCount":97},[],{"trials":1204,"activeCount":97},[],{"intervention":58,"totalTrials":93,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1208,"activeCount":97},[],{"trials":1210,"activeCount":97},[],{"trials":1212,"activeCount":97},[],{"trials":1214,"activeCount":97},[],{"trials":1216,"activeCount":97},[],{"trials":1218,"activeCount":93,"soonestReadout":53},[1219],{"nctId":56,"briefTitle":57,"status":109,"phases":1220,"primaryCompletion":53,"completion":53,"start":1221,"enrollment":160,"conditions":1222,"interventions":1223},[89],"2024-09-16",[162,15],[58],{"intervention":1225,"totalTrials":319,"cells":1226},"Ropivacaine",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1241,"PHASE3":1243,"PHASE4":1245,"NA":1261},{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":97},[1231],{"nctId":1232,"briefTitle":1233,"status":228,"phases":1234,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":477,"conditions":1237,"interventions":1239},"NCT03805360","The Erector Spinae Plane Block and Its Effect on Respiratory Status and Pain Management in Rib Fracture Patients",[85],"2020-01-10","2019-05-24",[1238],"Rib Fractures",[1225,1240],"Normal Saline Flush, 0.9% Injectable Solution",{"trials":1242,"activeCount":97},[],{"trials":1244,"activeCount":97},[],{"trials":1246,"activeCount":97},[1247],{"nctId":1248,"briefTitle":1249,"status":228,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1254,"interventions":1256},"NCT02570503","Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty",[88],"2021-02-11","2015-10",64,[1255],"Osteoarthritis, Knee",[1225,1257,1258,1259,1260],"Ketorolac","Clonidine","Epinephrine","0.9% sodium chloride",{"trials":1262,"activeCount":97},[],{"intervention":1264,"totalTrials":319,"cells":1265},"Lidocaine",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1284,"NA":1300},{"trials":1267,"activeCount":97},[],{"trials":1269,"activeCount":97},[],{"trials":1271,"activeCount":97},[],{"trials":1273,"activeCount":97},[1274],{"nctId":1275,"briefTitle":1276,"status":179,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT04500158","The Effect of Local Anesthesia on Control of Intraoperative Physiologic Parameters and Post Operative Comfort",[87],"2024-02-28","2020-11-03",59,[1282],"Pain, Procedural",[1264],{"trials":1285,"activeCount":97},[1286],{"nctId":1287,"briefTitle":1288,"status":228,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1295},"NCT02734940","Multimodal Analgesia in Cardiac Surgery (Pilot Study)",[88],"2017-02-01","2016-07-11",3,[1294],"Heart Diseases",[1264,1296,1297,1298,1299],"Unrestricted Fentanyl","Ketamine","Precedex","Duramorph",{"trials":1301,"activeCount":97},[],{"intervention":1303,"totalTrials":93,"cells":1304},"Fiber-Stat",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1324},{"trials":1306,"activeCount":97},[],{"trials":1308,"activeCount":97},[],{"trials":1310,"activeCount":97},[],{"trials":1312,"activeCount":97},[],{"trials":1314,"activeCount":97},[1315],{"nctId":1316,"briefTitle":1317,"status":228,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":319,"conditions":1321,"interventions":1323},"NCT00703092","Pilot Study:Role of Dietary Fiber in PCOS Anovulation",[88],"2010-03","2008-02",[1322],"PCOS",[1303],{"trials":1325,"activeCount":97},[],{"intervention":1327,"totalTrials":93,"cells":1328},"Canagliflozin",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1350},{"trials":1330,"activeCount":97},[],{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":97},[1339],{"nctId":1340,"briefTitle":1341,"status":179,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1348},"NCT02920918","Treatment of Diabetes in Patients With Systolic Heart Failure",[88],"2018-09","2016-10",36,[212,1347],"Diabetes Mellitus, Type 2",[1327,1349],"Sitagliptin",{"trials":1351,"activeCount":97},[],{"intervention":1349,"totalTrials":93,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1368},{"trials":1355,"activeCount":97},[],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[],{"trials":1361,"activeCount":97},[],{"trials":1363,"activeCount":97},[1364],{"nctId":1340,"briefTitle":1341,"status":179,"phases":1365,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1345,"conditions":1366,"interventions":1367},[88],[212,1347],[1327,1349],{"trials":1369,"activeCount":97},[],{"intervention":1371,"totalTrials":93,"cells":1372},"Chlorthalidone",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1392},{"trials":1374,"activeCount":97},[],{"trials":1376,"activeCount":97},[],{"trials":1378,"activeCount":97},[],{"trials":1380,"activeCount":97},[],{"trials":1382,"activeCount":97},[1383],{"nctId":1384,"briefTitle":1385,"status":207,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":97,"conditions":1389,"interventions":1391},"NCT02030314","The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone",[88],"2017-04-12","2013-07",[1390],"Resistant Hypertension in Kidney Transplant Patients",[1371],{"trials":1393,"activeCount":97},[],{"intervention":1395,"totalTrials":93,"cells":1396},"Venlafaxine",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1416},{"trials":1398,"activeCount":97},[],{"trials":1400,"activeCount":97},[],{"trials":1402,"activeCount":97},[],{"trials":1404,"activeCount":97},[],{"trials":1406,"activeCount":97},[1407],{"nctId":1408,"briefTitle":1409,"status":179,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":530,"conditions":1413,"interventions":1415},"NCT00205491","Pharmacological Intervention in Depression After Traumatic Brain Injury",[88],"2007-09","2004-10",[1414],"TBI (Traumatic Brain Injury)",[1395],{"trials":1417,"activeCount":97},[],{"intervention":1419,"totalTrials":93,"cells":1420},"Skin allograft",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1440},{"trials":1422,"activeCount":97},[],{"trials":1424,"activeCount":97},[],{"trials":1426,"activeCount":97},[],{"trials":1428,"activeCount":97},[],{"trials":1430,"activeCount":97},[1431],{"nctId":1432,"briefTitle":1433,"status":207,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":97,"conditions":1437,"interventions":1439},"NCT04162639","The Relationship Between Cadaveric Allograft Skin and HLA-Sensitivity in Burn Patients",[88],"2023-02","2021-02",[1438],"Burns",[1419],{"trials":1441,"activeCount":97},[],{"intervention":1443,"totalTrials":93,"cells":1444},"Ortho Tri Cyclen",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1466},{"trials":1446,"activeCount":97},[],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"trials":1452,"activeCount":97},[],{"trials":1454,"activeCount":97},[1455],{"nctId":1456,"briefTitle":1457,"status":179,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":331,"conditions":1461,"interventions":1465},"NCT00205504","Oral Contraceptives in the Metabolic Syndrome",[88],"2009-06","2005-06",[1462,1463,15,1464],"Metabolic Syndrome X","Insulin Resistance","Cardiovascular Diseases",[1443],{"trials":1467,"activeCount":97},[],{"intervention":1469,"totalTrials":93,"cells":1470},"alirocumab",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1492},{"trials":1472,"activeCount":97},[],{"trials":1474,"activeCount":97},[],{"trials":1476,"activeCount":97},[],{"trials":1478,"activeCount":97},[],{"trials":1480,"activeCount":97},[1481],{"nctId":1482,"briefTitle":1483,"status":179,"phases":1484,"primaryCompletion":1485,"completion":1486,"start":1487,"enrollment":19,"conditions":1488,"interventions":1491},"NCT02938949","Alirocumab in Patients With Acute Myocardial Infarction",[88],"2018-08","2018-08-16","2017-01",[1489,1490],"Myocardial Infarction","Hypercholesterolemia",[1469],{"trials":1493,"activeCount":97},[],{"intervention":1495,"totalTrials":93,"cells":1496},"Ropivacaine 0.25%-NaCl 0.9% Injectable Solution",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1519},{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":97},[],{"trials":1502,"activeCount":97},[],{"trials":1504,"activeCount":97},[],{"trials":1506,"activeCount":97},[1507],{"nctId":1508,"briefTitle":1509,"status":207,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":97,"conditions":1514,"interventions":1517},"NCT03874806","Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block",[88],"2020-07-01","2020-12-31","2019-07-01",[1515,1516],"Pain, Postoperative","Pain, Chest",[1495,1518],"Ropivacaine 0.2%-NaCl 0.9% Injectable Solution",{"trials":1520,"activeCount":97},[],{"intervention":1518,"totalTrials":93,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1529,"PHASE4":1531,"NA":1537},{"trials":1524,"activeCount":97},[],{"trials":1526,"activeCount":97},[],{"trials":1528,"activeCount":97},[],{"trials":1530,"activeCount":97},[],{"trials":1532,"activeCount":97},[1533],{"nctId":1508,"briefTitle":1509,"status":207,"phases":1534,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":97,"conditions":1535,"interventions":1536},[88],[1515,1516],[1495,1518],{"trials":1538,"activeCount":97},[],{"intervention":1540,"totalTrials":93,"cells":1541},"Cetirizine",{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1548,"PHASE4":1550,"NA":1560},{"trials":1543,"activeCount":97},[],{"trials":1545,"activeCount":97},[],{"trials":1547,"activeCount":97},[],{"trials":1549,"activeCount":97},[],{"trials":1551,"activeCount":97},[1552],{"nctId":1553,"briefTitle":1554,"status":228,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":272,"enrollment":1292,"conditions":1557,"interventions":1559},"NCT01825655","Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching",[88],"2017-11",[1558],"Pruritus",[1540],{"trials":1561,"activeCount":97},[],{"intervention":1563,"totalTrials":93,"cells":1564},"Tamoxifen Citrate 10Mg Tab",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1571,"PHASE4":1573,"NA":1586},{"trials":1566,"activeCount":97},[],{"trials":1568,"activeCount":97},[],{"trials":1570,"activeCount":97},[],{"trials":1572,"activeCount":97},[],{"trials":1574,"activeCount":97},[1575],{"nctId":1576,"briefTitle":1577,"status":207,"phases":1578,"primaryCompletion":1579,"completion":1580,"start":1581,"enrollment":97,"conditions":1582,"interventions":1584},"NCT04933240","Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial",[88],"2024-06","2024-12","2022-05",[1583],"Vaginal Bleeding",[1563,1585],"Estradiol",{"trials":1587,"activeCount":97},[],{"intervention":1585,"totalTrials":93,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1604},{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[],{"trials":1595,"activeCount":97},[],{"trials":1597,"activeCount":97},[],{"trials":1599,"activeCount":97},[1600],{"nctId":1576,"briefTitle":1577,"status":207,"phases":1601,"primaryCompletion":1579,"completion":1580,"start":1581,"enrollment":97,"conditions":1602,"interventions":1603},[88],[1583],[1563,1585],{"trials":1605,"activeCount":97},[],{"intervention":1607,"totalTrials":93,"cells":1608},"Acamprosate",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1617,"NA":1627},{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[],{"trials":1614,"activeCount":97},[],{"trials":1616,"activeCount":97},[],{"trials":1618,"activeCount":97},[1619],{"nctId":1620,"briefTitle":1621,"status":228,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1460,"enrollment":442,"conditions":1624,"interventions":1626},"NCT00249379","Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees",[88],"2008-08",[1625],"Alcohol Dependence",[1607],{"trials":1628,"activeCount":97},[],{"intervention":1630,"totalTrials":93,"cells":1631},"Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1651},{"trials":1633,"activeCount":97},[],{"trials":1635,"activeCount":97},[],{"trials":1637,"activeCount":97},[],{"trials":1639,"activeCount":97},[],{"trials":1641,"activeCount":97},[1642],{"nctId":1643,"briefTitle":1644,"status":207,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":97,"conditions":1648,"interventions":1649},"NCT03961048","Ideal Initial Bolus and Infusion Rate for Erector Spinae Plane Block Catheters",[88],"2020-09","2019-07-23",[1515,1516],[1630,1650],"Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally",{"trials":1652,"activeCount":97},[],{"intervention":1650,"totalTrials":93,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1669},{"trials":1656,"activeCount":97},[],{"trials":1658,"activeCount":97},[],{"trials":1660,"activeCount":97},[],{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":97},[1665],{"nctId":1643,"briefTitle":1644,"status":207,"phases":1666,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":97,"conditions":1667,"interventions":1668},[88],[1515,1516],[1630,1650],{"trials":1670,"activeCount":97},[],{"intervention":1257,"totalTrials":93,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1687},{"trials":1674,"activeCount":97},[],{"trials":1676,"activeCount":97},[],{"trials":1678,"activeCount":97},[],{"trials":1680,"activeCount":97},[],{"trials":1682,"activeCount":97},[1683],{"nctId":1248,"briefTitle":1249,"status":228,"phases":1684,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1685,"interventions":1686},[88],[1255],[1225,1257,1258,1259,1260],{"trials":1688,"activeCount":97},[],{"intervention":1258,"totalTrials":93,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1705},{"trials":1692,"activeCount":97},[],{"trials":1694,"activeCount":97},[],{"trials":1696,"activeCount":97},[],{"trials":1698,"activeCount":97},[],{"trials":1700,"activeCount":97},[1701],{"nctId":1248,"briefTitle":1249,"status":228,"phases":1702,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1703,"interventions":1704},[88],[1255],[1225,1257,1258,1259,1260],{"trials":1706,"activeCount":97},[],{"intervention":1259,"totalTrials":93,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1723},{"trials":1710,"activeCount":97},[],{"trials":1712,"activeCount":97},[],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[],{"trials":1718,"activeCount":97},[1719],{"nctId":1248,"briefTitle":1249,"status":228,"phases":1720,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1721,"interventions":1722},[88],[1255],[1225,1257,1258,1259,1260],{"trials":1724,"activeCount":97},[],{"intervention":1260,"totalTrials":93,"cells":1726},{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1741},{"trials":1728,"activeCount":97},[],{"trials":1730,"activeCount":97},[],{"trials":1732,"activeCount":97},[],{"trials":1734,"activeCount":97},[],{"trials":1736,"activeCount":97},[1737],{"nctId":1248,"briefTitle":1249,"status":228,"phases":1738,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1739,"interventions":1740},[88],[1255],[1225,1257,1258,1259,1260],{"trials":1742,"activeCount":97},[],{"intervention":1744,"totalTrials":93,"cells":1745},"Diltiazem Oral Product",{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1766},{"trials":1747,"activeCount":97},[],{"trials":1749,"activeCount":97},[],{"trials":1751,"activeCount":97},[],{"trials":1753,"activeCount":97},[],{"trials":1755,"activeCount":97},[1756],{"nctId":1757,"briefTitle":1758,"status":179,"phases":1759,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":359,"conditions":1762,"interventions":1764},"NCT03472495","Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation\u002FFlutter Trial",[88],"2021-03-21","2018-06-01",[1763],"Atrial Fibrillation and Flutter",[1744,1765],"Diltiazem Injectable Product",{"trials":1767,"activeCount":97},[],{"intervention":1765,"totalTrials":93,"cells":1769},{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1774,"PHASE3":1776,"PHASE4":1778,"NA":1784},{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[],{"trials":1775,"activeCount":97},[],{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[1780],{"nctId":1757,"briefTitle":1758,"status":179,"phases":1781,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":359,"conditions":1782,"interventions":1783},[88],[1763],[1744,1765],{"trials":1785,"activeCount":97},[],{"intervention":1787,"totalTrials":93,"cells":1788},"metformin",{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1810},{"trials":1790,"activeCount":97},[],{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[],{"trials":1796,"activeCount":97},[],{"trials":1798,"activeCount":97},[1799],{"nctId":1800,"briefTitle":1801,"status":228,"phases":1802,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":9,"conditions":1806,"interventions":1809},"NCT00682890","Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)",[88],"2009-12","2010-01","2005-11",[1807,1322,1808],"Polycystic Ovary Syndrome","Insulin Sensitivity",[1787],{"trials":1811,"activeCount":97},[],{"intervention":1813,"totalTrials":93,"cells":1814},"Ortho Cyclen®",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1836},{"trials":1816,"activeCount":97},[],{"trials":1818,"activeCount":97},[],{"trials":1820,"activeCount":97},[],{"trials":1822,"activeCount":97},[],{"trials":1824,"activeCount":97},[1825],{"nctId":1826,"briefTitle":1827,"status":179,"phases":1828,"primaryCompletion":1829,"completion":1829,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1835},"NCT01475513","Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women",[88],"2014-05-28","2011-11",47,[1808,1833,1834],"Cardiovascular Risk","Perimenopausal Disorder",[1813],{"trials":1837,"activeCount":97},[],{"intervention":1839,"totalTrials":93,"cells":1840},"Metoprolol Tartrate Oral",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1849,"NA":1862},{"trials":1842,"activeCount":97},[],{"trials":1844,"activeCount":97},[],{"trials":1846,"activeCount":97},[],{"trials":1848,"activeCount":97},[],{"trials":1850,"activeCount":97},[1851],{"nctId":1852,"briefTitle":1853,"status":179,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1861},"NCT03008382","Interstitial Cystitis: Examination of the Central Autonomic Network",[88],"2022-03-16","2017-03-01",72,[1859,1860],"Interstitial Cystitis\u002FPainful Bladder Syndrome","Myofascial Pelvic Pain",[1839],{"trials":1863,"activeCount":97},[],{"intervention":1865,"totalTrials":93,"cells":1866},"nesiritide",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1887},{"trials":1868,"activeCount":97},[],{"trials":1870,"activeCount":97},[],{"trials":1872,"activeCount":97},[],{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[1877],{"nctId":1878,"briefTitle":1879,"status":228,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":319,"conditions":1883,"interventions":1886},"NCT01836809","Nesiritide and Renal Function After the Total Artificial Heart",[88],"2014-05","2013-04",[1884,1885],"Congestive Heart Failure","Cardiorenal Syndrome",[1865],{"trials":1888,"activeCount":97},[],{"intervention":1890,"totalTrials":93,"cells":1891},"Ramelteon Pill",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1909},{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[],{"trials":1897,"activeCount":97},[],{"trials":1899,"activeCount":97},[],{"trials":1901,"activeCount":97},[1902],{"nctId":1903,"briefTitle":1904,"status":179,"phases":1905,"primaryCompletion":1906,"completion":1906,"start":1290,"enrollment":294,"conditions":1907,"interventions":1908},"NCT03091738","Ramelteon for Treatment of Insomnia in Cirrhosis",[88],"2018-10-01",[786],[1890],{"trials":1910,"activeCount":97},[],{"intervention":1296,"totalTrials":93,"cells":1912},{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1921,"NA":1927},{"trials":1914,"activeCount":97},[],{"trials":1916,"activeCount":97},[],{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[],{"trials":1922,"activeCount":97},[1923],{"nctId":1287,"briefTitle":1288,"status":228,"phases":1924,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1925,"interventions":1926},[88],[1294],[1264,1296,1297,1298,1299],{"trials":1928,"activeCount":97},[],{"intervention":1297,"totalTrials":93,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1945},{"trials":1932,"activeCount":97},[],{"trials":1934,"activeCount":97},[],{"trials":1936,"activeCount":97},[],{"trials":1938,"activeCount":97},[],{"trials":1940,"activeCount":97},[1941],{"nctId":1287,"briefTitle":1288,"status":228,"phases":1942,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1943,"interventions":1944},[88],[1294],[1264,1296,1297,1298,1299],{"trials":1946,"activeCount":97},[],{"intervention":1298,"totalTrials":93,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1963},{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[1959],{"nctId":1287,"briefTitle":1288,"status":228,"phases":1960,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1961,"interventions":1962},[88],[1294],[1264,1296,1297,1298,1299],{"trials":1964,"activeCount":97},[],{"intervention":1299,"totalTrials":93,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1981},{"trials":1968,"activeCount":97},[],{"trials":1970,"activeCount":97},[],{"trials":1972,"activeCount":97},[],{"trials":1974,"activeCount":97},[],{"trials":1976,"activeCount":97},[1977],{"nctId":1287,"briefTitle":1288,"status":228,"phases":1978,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1979,"interventions":1980},[88],[1294],[1264,1296,1297,1298,1299],{"trials":1982,"activeCount":97},[],{"intervention":1984,"totalTrials":93,"cells":1985},"Midazolam",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":2006},{"trials":1987,"activeCount":97},[],{"trials":1989,"activeCount":97},[],{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"trials":1995,"activeCount":97},[1996],{"nctId":1997,"briefTitle":1998,"status":207,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":2000,"enrollment":97,"conditions":2001,"interventions":2004},"NCT00871039","Pilot Study Evaluating Stress Response and Immune Function in Mechanically Ventilated Patients With Alcohol Use Disorders Treated With Propofol or Midazolam",[88],"2009-03",[2002,2003],"Alcoholism","Respiration, Artificial",[2005,1984],"Propofol",{"trials":2007,"activeCount":97},[],{"intervention":2009,"totalTrials":93,"cells":2010},"Vaginal Misoprostol",{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2019,"NA":2032},{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":97},[],{"trials":2016,"activeCount":97},[],{"trials":2018,"activeCount":97},[],{"trials":2020,"activeCount":97},[2021],{"nctId":2022,"briefTitle":2023,"status":179,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2030},"NCT03134183","24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E",[88],"2017-08-01","2016-11-19",70,[2029],"Abortion, Second Trimester",[2009,2031],"Buccal Misoprostol",{"trials":2033,"activeCount":97},[],{"intervention":2031,"totalTrials":93,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2050},{"trials":2037,"activeCount":97},[],{"trials":2039,"activeCount":97},[],{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"trials":2045,"activeCount":97},[2046],{"nctId":2022,"briefTitle":2023,"status":179,"phases":2047,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2048,"interventions":2049},[88],[2029],[2009,2031],{"trials":2051,"activeCount":97},[],{"intervention":366,"totalTrials":477,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2078,"PHASE3":2088,"PHASE4":2094,"NA":2096},{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[2058,2067],{"nctId":2059,"briefTitle":2060,"status":179,"phases":2061,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":160,"conditions":2064,"interventions":2065},"NCT00003079","Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma",[85],"2001-05","1997-09",[21,31],[2066,366],"bryostatin 1",{"nctId":2068,"briefTitle":2069,"status":179,"phases":2070,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":1194,"conditions":2073,"interventions":2076},"NCT00002818","High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies",[85],"2001-02","1995-02",[2074,21,31,2075],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Multiple Myeloma and Plasma Cell Neoplasm",[366,2077],"deoxycytidine",{"trials":2079,"activeCount":97},[2080],{"nctId":2081,"briefTitle":2082,"status":179,"phases":2083,"primaryCompletion":2084,"completion":1460,"start":2085,"conditions":2086,"interventions":2087},"NCT00017342","Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia",[86],"2004-09","2001-07",[21],[2066,366],{"trials":2089,"activeCount":97},[2090],{"nctId":354,"briefTitle":355,"status":179,"phases":2091,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":2092,"interventions":2093},[86,87],[21,31,361],[363,364,365,366,367,368],{"trials":2095,"activeCount":97},[],{"trials":2097,"activeCount":97},[],{"intervention":2099,"totalTrials":319,"cells":2100},"SUBLOCADE",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2107,"PHASE4":2124,"NA":2126},{"trials":2102,"activeCount":97},[],{"trials":2104,"activeCount":97},[],{"trials":2106,"activeCount":97},[],{"trials":2108,"activeCount":97},[2109,2117],{"nctId":2110,"briefTitle":2111,"status":207,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":97,"conditions":2115,"interventions":2116},"NCT04523792","Virginia Opioid Treatment-Emergency Department",[87],"2021-12-31","2021-01-01",[532],[2099],{"nctId":2118,"briefTitle":2119,"status":228,"phases":2120,"primaryCompletion":2121,"completion":2121,"start":261,"enrollment":359,"conditions":2122,"interventions":2123},"NCT03818399","Virginia Opioid Overdose Treatment InitiatVE",[87],"2021-02-24",[532],[2099],{"trials":2125,"activeCount":97},[],{"trials":2127,"activeCount":97},[],{"intervention":2129,"totalTrials":319,"cells":2130},"Filgrastim",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2162,"PHASE4":2168,"NA":2170},{"trials":2132,"activeCount":97},[],{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[2137],{"nctId":2138,"briefTitle":2139,"status":179,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":273,"conditions":2143,"interventions":2159},"NCT02593123","Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis",[86],"2022-03-18","2015-11-04",[2144,2145,31,21,2146,2147,2148,2149,2150,2151,361,2152,2153,2154,2155,2156,2157,2158],"Hodgkin's Lymphoma","Lymphoid Leukemia","Myeloma","Acute Lymphocytic Leukemia","Non Hodgkin Lymphoma","Chronic Lymphocytic Leukemia","Multiple Myeloma","Chronic Myelogenous Leukemia","Recurrent Acute Myeloid Leukemia, Adult","Recurrent Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Plasma Cell Myeloma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia",[2160,2161,2129],"mycophenolate mofetil","Sargramostim",{"trials":2163,"activeCount":97},[2164],{"nctId":354,"briefTitle":355,"status":179,"phases":2165,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":2166,"interventions":2167},[86,87],[21,31,361],[363,364,365,366,367,368],{"trials":2169,"activeCount":97},[],{"trials":2171,"activeCount":97},[],{"intervention":2173,"totalTrials":93,"cells":2174},"allergen extract",{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2193,"NA":2195},{"trials":2176,"activeCount":97},[],{"trials":2178,"activeCount":97},[],{"trials":2180,"activeCount":97},[],{"trials":2182,"activeCount":97},[2183],{"nctId":2184,"briefTitle":2185,"status":228,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":2189,"conditions":2190,"interventions":2192},"NCT02676765","Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy",[87],"2018-01-18","2016-06",58,[2191],"Immunologic Desensitization",[2173],{"trials":2194,"activeCount":97},[],{"trials":2196,"activeCount":97},[],{"intervention":2198,"totalTrials":93,"cells":2199},"DCI",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2217,"NA":2219},{"trials":2201,"activeCount":97},[],{"trials":2203,"activeCount":97},[],{"trials":2205,"activeCount":97},[],{"trials":2207,"activeCount":97},[2208],{"nctId":2209,"briefTitle":2210,"status":228,"phases":2211,"primaryCompletion":2212,"completion":2213,"start":2071,"enrollment":2214,"conditions":2215,"interventions":2216},"NCT00497653","Oral Administration of DCI to Women With PCOS",[86,87],"2007-07","2009-07",13,[1807],[2198],{"trials":2218,"activeCount":97},[],{"trials":2220,"activeCount":97},[],{"intervention":2222,"totalTrials":93,"cells":2223},"Plasma",{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2242,"NA":2244},{"trials":2225,"activeCount":97},[],{"trials":2227,"activeCount":97},[],{"trials":2229,"activeCount":97},[],{"trials":2231,"activeCount":97},[2232],{"nctId":2233,"briefTitle":2234,"status":207,"phases":2235,"primaryCompletion":2236,"completion":2236,"start":2237,"enrollment":97,"conditions":2238,"interventions":2240},"NCT02303964","Pre-Hospital Use of Plasma for Traumatic Hemorrhage",[86,87],"2016-01","2014-11",[2239],"Shock, Hemorrhagic",[2222,2241],"Normal saline",{"trials":2243,"activeCount":97},[],{"trials":2245,"activeCount":97},[],{"intervention":2241,"totalTrials":93,"cells":2247},{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2254,"PHASE4":2260,"NA":2262},{"trials":2249,"activeCount":97},[],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[2256],{"nctId":2233,"briefTitle":2234,"status":207,"phases":2257,"primaryCompletion":2236,"completion":2236,"start":2237,"enrollment":97,"conditions":2258,"interventions":2259},[86,87],[2239],[2222,2241],{"trials":2261,"activeCount":97},[],{"trials":2263,"activeCount":97},[],{"intervention":2265,"totalTrials":93,"cells":2266},"Hepatitis A Vaccine",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2286,"NA":2288},{"trials":2268,"activeCount":97},[],{"trials":2270,"activeCount":97},[],{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[2275],{"nctId":2276,"briefTitle":2277,"status":228,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT00201448","Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women",[86,87],"2009-10","2007-06",82,[2283],"Cytomegalovirus Infections",[2265,2285],"Towne CMV Vaccine",{"trials":2287,"activeCount":97},[],{"trials":2289,"activeCount":97},[],{"intervention":2285,"totalTrials":93,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2298,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":97},[],{"trials":2295,"activeCount":97},[],{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[2300],{"nctId":2276,"briefTitle":2277,"status":228,"phases":2301,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":2302,"interventions":2303},[86,87],[2283],[2265,2285],{"trials":2305,"activeCount":97},[],{"trials":2307,"activeCount":97},[],{"intervention":2309,"totalTrials":93,"cells":2310},"Zonisamide",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2317,"PHASE4":2327,"NA":2329},{"trials":2312,"activeCount":97},[],{"trials":2314,"activeCount":97},[],{"trials":2316,"activeCount":97},[],{"trials":2318,"activeCount":97},[2319],{"nctId":2320,"briefTitle":2321,"status":179,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":1344,"enrollment":2324,"conditions":2325,"interventions":2326},"NCT02900352","Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action",[87],"2021-04-22",156,[787],[2309],{"trials":2328,"activeCount":97},[],{"trials":2330,"activeCount":97},[],{"intervention":2332,"totalTrials":93,"cells":2333},"Anakinra 100 mg",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2340,"PHASE4":2351,"NA":2353},{"trials":2335,"activeCount":97},[],{"trials":2337,"activeCount":97},[],{"trials":2339,"activeCount":97},[],{"trials":2341,"activeCount":97},[2342],{"nctId":2343,"briefTitle":2344,"status":179,"phases":2345,"primaryCompletion":2346,"completion":2346,"start":2347,"enrollment":2348,"conditions":2349,"interventions":2350},"NCT01950299","Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)",[86,87],"2018-12-23","2014-07-01",99,[244],[2332,2332],{"trials":2352,"activeCount":97},[],{"trials":2354,"activeCount":97},[],{"intervention":2356,"totalTrials":93,"cells":2357},"Peginterferon-alpha-2b",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2364,"PHASE4":2378,"NA":2380},{"trials":2359,"activeCount":97},[],{"trials":2361,"activeCount":97},[],{"trials":2363,"activeCount":97},[],{"trials":2365,"activeCount":97},[2366],{"nctId":2367,"briefTitle":2368,"status":179,"phases":2369,"primaryCompletion":2370,"completion":2370,"start":2371,"enrollment":2372,"conditions":2373,"interventions":2375},"NCT00248339","Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection",[87],"2005-07","2002-05",150,[2374],"Hepatitis C",[2356,2376,2377],"Ribavirin","Epoetin-alpha",{"trials":2379,"activeCount":97},[],{"trials":2381,"activeCount":97},[],{"intervention":2376,"totalTrials":93,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2390,"PHASE4":2396,"NA":2398},{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[],{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[2392],{"nctId":2367,"briefTitle":2368,"status":179,"phases":2393,"primaryCompletion":2370,"completion":2370,"start":2371,"enrollment":2372,"conditions":2394,"interventions":2395},[87],[2374],[2356,2376,2377],{"trials":2397,"activeCount":97},[],{"trials":2399,"activeCount":97},[],{"intervention":2377,"totalTrials":93,"cells":2401},{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2414,"NA":2416},{"trials":2403,"activeCount":97},[],{"trials":2405,"activeCount":97},[],{"trials":2407,"activeCount":97},[],{"trials":2409,"activeCount":97},[2410],{"nctId":2367,"briefTitle":2368,"status":179,"phases":2411,"primaryCompletion":2370,"completion":2370,"start":2371,"enrollment":2372,"conditions":2412,"interventions":2413},[87],[2374],[2356,2376,2377],{"trials":2415,"activeCount":97},[],{"trials":2417,"activeCount":97},[],{"intervention":2419,"totalTrials":93,"cells":2420},"leukocyte platelet rich fibrin",{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2427,"PHASE4":2438,"NA":2440},{"trials":2422,"activeCount":97},[],{"trials":2424,"activeCount":97},[],{"trials":2426,"activeCount":97},[],{"trials":2428,"activeCount":97},[2429],{"nctId":2430,"briefTitle":2431,"status":207,"phases":2432,"primaryCompletion":2433,"completion":2433,"start":1581,"enrollment":97,"conditions":2434,"interventions":2437},"NCT04978324","Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF)",[87],"2022-12",[2435,2436],"Periodontitis Chronic Generalized Severe","Periodontitis Chronic Generalized Moderate",[2419],{"trials":2439,"activeCount":97},[],{"trials":2441,"activeCount":97},[],{"intervention":2443,"totalTrials":93,"cells":2444},"13C-Methacetin",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2462,"NA":2464},{"trials":2446,"activeCount":97},[],{"trials":2448,"activeCount":97},[],{"trials":2450,"activeCount":97},[],{"trials":2452,"activeCount":97},[2453],{"nctId":2454,"briefTitle":2455,"status":179,"phases":2456,"primaryCompletion":2457,"completion":2457,"start":2458,"enrollment":138,"conditions":2459,"interventions":2461},"NCT00244569","Development of a Breath Test for Monitoring Patients With Liver Disease",[87],"2007-04","2005-09",[2460,786],"Fatty Liver",[2443],{"trials":2463,"activeCount":97},[],{"trials":2465,"activeCount":97},[],{"intervention":2467,"totalTrials":93,"cells":2468},"Escitalopram",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2475,"PHASE4":2487,"NA":2489},{"trials":2470,"activeCount":97},[],{"trials":2472,"activeCount":97},[],{"trials":2474,"activeCount":97},[],{"trials":2476,"activeCount":97},[2477],{"nctId":2478,"briefTitle":2479,"status":179,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":2483,"conditions":2484,"interventions":2486},"NCT00732901","Clinical Neurobiology of Serotonin and Addiction",[86,87],"2013-02","2008-06",160,[2485],"Cocaine Dependence",[2467],{"trials":2488,"activeCount":97},[],{"trials":2490,"activeCount":97},[],{"intervention":2492,"totalTrials":93,"cells":2493},"Melatonin",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2511,"NA":2513},{"trials":2495,"activeCount":97},[],{"trials":2497,"activeCount":97},[],{"trials":2499,"activeCount":97},[],{"trials":2501,"activeCount":97},[2502],{"nctId":2503,"briefTitle":2504,"status":228,"phases":2505,"primaryCompletion":2506,"completion":2506,"start":2507,"enrollment":783,"conditions":2508,"interventions":2510},"NCT02332928","Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy",[87],"2021-06-02","2015-03-25",[2509],"Breast Cancer - Female",[2492],{"trials":2512,"activeCount":97},[],{"trials":2514,"activeCount":97},[],{"intervention":2516,"totalTrials":93,"cells":2517},"Ascorbic Acid 500Mg\u002FMl Inj",{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2524,"PHASE4":2537,"NA":2539},{"trials":2519,"activeCount":97},[],{"trials":2521,"activeCount":97},[],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[2526],{"nctId":2527,"briefTitle":2528,"status":207,"phases":2529,"primaryCompletion":2530,"completion":2531,"start":2532,"enrollment":97,"conditions":2533,"interventions":2535},"NCT04088591","High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda",[87],"2023-11","2023-12","2022-10",[2534],"Sepsis",[2516,2536],"Dextrose in Water",{"trials":2538,"activeCount":97},[],{"trials":2540,"activeCount":97},[],{"intervention":2536,"totalTrials":93,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2549,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[],{"trials":2550,"activeCount":97},[2551],{"nctId":2527,"briefTitle":2528,"status":207,"phases":2552,"primaryCompletion":2530,"completion":2531,"start":2532,"enrollment":97,"conditions":2553,"interventions":2554},[87],[2534],[2516,2536],{"trials":2556,"activeCount":97},[],{"trials":2558,"activeCount":97},[],{"intervention":365,"totalTrials":93,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2573,"NA":2575},{"trials":2562,"activeCount":97},[],{"trials":2564,"activeCount":97},[],{"trials":2566,"activeCount":97},[],{"trials":2568,"activeCount":97},[2569],{"nctId":354,"briefTitle":355,"status":179,"phases":2570,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":2571,"interventions":2572},[86,87],[21,31,361],[363,364,365,366,367,368],{"trials":2574,"activeCount":97},[],{"trials":2576,"activeCount":97},[],{"intervention":367,"totalTrials":93,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":97},[],{"trials":2582,"activeCount":97},[],{"trials":2584,"activeCount":97},[],{"trials":2586,"activeCount":97},[2587],{"nctId":354,"briefTitle":355,"status":179,"phases":2588,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":2589,"interventions":2590},[86,87],[21,31,361],[363,364,365,366,367,368],{"trials":2592,"activeCount":97},[],{"trials":2594,"activeCount":97},[],{"intervention":368,"totalTrials":93,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2609,"NA":2611},{"trials":2598,"activeCount":97},[],{"trials":2600,"activeCount":97},[],{"trials":2602,"activeCount":97},[],{"trials":2604,"activeCount":97},[2605],{"nctId":354,"briefTitle":355,"status":179,"phases":2606,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":2607,"interventions":2608},[86,87],[21,31,361],[363,364,365,366,367,368],{"trials":2610,"activeCount":97},[],{"trials":2612,"activeCount":97},[],{"intervention":2614,"totalTrials":93,"cells":2615},"Botulinum toxin A + exercise",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2632,"NA":2634},{"trials":2617,"activeCount":97},[],{"trials":2619,"activeCount":97},[],{"trials":2621,"activeCount":97},[],{"trials":2623,"activeCount":97},[2624],{"nctId":2625,"briefTitle":2626,"status":228,"phases":2627,"primaryCompletion":2482,"completion":2482,"start":2628,"enrollment":232,"conditions":2629,"interventions":2631},"NCT00496964","Botox for Non-surgical Lateral Release in Patellofemoral Pain",[87],"2005-05",[2630],"Patellofemoral Pain Syndrome",[2614],{"trials":2633,"activeCount":97},[],{"trials":2635,"activeCount":97},[],{"intervention":2066,"totalTrials":477,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2667,"PHASE3":2673,"PHASE4":2675,"NA":2677},{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[2642,2654,2658],{"nctId":2643,"briefTitle":2644,"status":179,"phases":2645,"primaryCompletion":2646,"completion":2647,"start":2648,"enrollment":252,"conditions":2649,"interventions":2652},"NCT00006022","Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer",[85],"2003-10","2004-01","2000-09",[2650,2651],"Kidney Cancer","Melanoma (Skin)",[2653,2066],"aldesleukin",{"nctId":2059,"briefTitle":2060,"status":179,"phases":2655,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":160,"conditions":2656,"interventions":2657},[85],[21,31],[2066,366],{"nctId":2659,"briefTitle":2660,"status":179,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":810,"conditions":2664,"interventions":2665},"NCT00005580","Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma",[85],"2006-08","1998-09",[21,31],[2066,2666],"fludarabine phosphate",{"trials":2668,"activeCount":97},[2669],{"nctId":2081,"briefTitle":2082,"status":179,"phases":2670,"primaryCompletion":2084,"completion":1460,"start":2085,"conditions":2671,"interventions":2672},[86],[21],[2066,366],{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[],{"intervention":2680,"totalTrials":1292,"cells":2681},"sorafenib tosylate",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2709,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[2686,2697],{"nctId":2687,"briefTitle":2688,"status":179,"phases":2689,"primaryCompletion":383,"completion":2690,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2695},"NCT01450384","Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors",[85],"2015-09","2011-10",37,[2694],"Unspecified Adult Solid Tumor",[2680,2696],"pemetrexed disodium",{"nctId":2698,"briefTitle":2699,"status":179,"phases":2700,"primaryCompletion":2701,"completion":2702,"start":2703,"enrollment":2704,"conditions":2705,"interventions":2707},"NCT01075113","Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer",[85],"2017-02-02","2019-07-18","2010-08-10",16,[2706],"Liver Cancer",[2680,2708],"vorinostat",{"trials":2710,"activeCount":97},[2711],{"nctId":2712,"briefTitle":2713,"status":179,"phases":2714,"primaryCompletion":2715,"completion":2716,"start":2717,"enrollment":1831,"conditions":2718,"interventions":2723},"NCT01817751","Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma",[86],"2020-08-27","2023-05-12","2013-04-11",[2719,2720,2721,2722],"Glioblastoma","Recurrent Adult Brain Neoplasm","Malignant Glioma","WHO Grade III Glioma",[2680,2724,2725],"valproic acid","sildenafil citrate",{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"intervention":2733,"totalTrials":1292,"cells":2734},"Kovanaze Nasal Spray",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2736,"activeCount":97},[],{"trials":2738,"activeCount":97},[],{"trials":2740,"activeCount":97},[2741,2752,2760],{"nctId":2742,"briefTitle":2743,"status":207,"phases":2744,"primaryCompletion":2745,"completion":2746,"start":1646,"enrollment":97,"conditions":2747,"interventions":2750},"NCT04104789","Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General",[86],"2021-09","2021-10",[2748,2749],"Caries,Dental","Apical Periodontitis",[2733,2751],"Articaine",{"nctId":2753,"briefTitle":2754,"status":207,"phases":2755,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":97,"conditions":2758,"interventions":2759},"NCT04105985","Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics",[86],"2021-08","2020-08",[2748,2749],[2733,2751],{"nctId":2761,"briefTitle":2762,"status":228,"phases":2763,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":1292,"conditions":2766,"interventions":2767},"NCT03962634","Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric",[86],"2019-09-17","2019-08-28",[2748,2749],[2733,2751],{"trials":2769,"activeCount":97},[],{"trials":2771,"activeCount":97},[],{"trials":2773,"activeCount":97},[],{"intervention":2751,"totalTrials":1292,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2777,"activeCount":97},[],{"trials":2779,"activeCount":97},[],{"trials":2781,"activeCount":97},[2782,2786,2790],{"nctId":2742,"briefTitle":2743,"status":207,"phases":2783,"primaryCompletion":2745,"completion":2746,"start":1646,"enrollment":97,"conditions":2784,"interventions":2785},[86],[2748,2749],[2733,2751],{"nctId":2753,"briefTitle":2754,"status":207,"phases":2787,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":97,"conditions":2788,"interventions":2789},[86],[2748,2749],[2733,2751],{"nctId":2761,"briefTitle":2762,"status":228,"phases":2791,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":1292,"conditions":2792,"interventions":2793},[86],[2748,2749],[2733,2751],{"trials":2795,"activeCount":97},[],{"trials":2797,"activeCount":97},[],{"trials":2799,"activeCount":97},[],{"intervention":2801,"totalTrials":1292,"cells":2802},"Ascorbic Acid",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2820,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2804,"activeCount":97},[],{"trials":2806,"activeCount":97},[2807],{"nctId":2808,"briefTitle":2809,"status":228,"phases":2810,"primaryCompletion":2811,"completion":2811,"start":2812,"enrollment":2813,"conditions":2814,"interventions":2819},"NCT02762331","High Dose Vitamin C in Cardiac Surgery Patients",[85],"2018-03-13","2017-01-01",6,[2815,2816,2817,2818],"Disorder of Vitamin C","Atrial Fibrillation","Complications Due to Coronary Artery Bypass Graft","Heart Valve Disease",[2801],{"trials":2821,"activeCount":97},[2822,2833],{"nctId":2823,"briefTitle":2824,"status":179,"phases":2825,"primaryCompletion":240,"completion":240,"start":2826,"enrollment":2827,"conditions":2828,"interventions":2832},"NCT01434121","Ascorbic Acid (Vitamin C) Infusion in Human Sepsis",[85,86],"2010-05",24,[2534,2829,2830,2831],"Septic Shock","Hypotension","Acute Lung Injury",[2801],{"nctId":2834,"briefTitle":2835,"status":179,"phases":2836,"primaryCompletion":2837,"completion":2838,"start":2839,"enrollment":669,"conditions":2840,"interventions":2841},"NCT02106975","Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury",[86],"2017-11-16","2018-01-08","2014-04",[2831,2534],[2801],{"trials":2843,"activeCount":97},[],{"trials":2845,"activeCount":97},[],{"trials":2847,"activeCount":97},[],{"intervention":2849,"totalTrials":319,"cells":2850},"Placebos",{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2852,"activeCount":97},[],{"trials":2854,"activeCount":97},[],{"trials":2856,"activeCount":97},[2857,2869],{"nctId":2858,"briefTitle":2859,"status":179,"phases":2860,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":319,"conditions":2863,"interventions":2867},"NCT04463004","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation",[86],"2020-11-30","2020-09-02",[2864,2865,2866],"COVID-19","Sars-CoV2","Pneumonia",[2868,2849],"Mavrilimumab",{"nctId":2870,"briefTitle":2871,"status":179,"phases":2872,"primaryCompletion":2873,"completion":2873,"start":2874,"enrollment":16,"conditions":2875,"interventions":2877},"NCT03098433","Effects of Liothyronine on Energy Expenditure and Cardiovascular Function",[85,86],"2019-06-24","2017-10-20",[2876],"Healthy",[2878,2879,2849],"Liothyronine","Levothyroxine",{"trials":2881,"activeCount":97},[],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[],{"intervention":2878,"totalTrials":319,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2889,"activeCount":97},[],{"trials":2891,"activeCount":97},[],{"trials":2893,"activeCount":97},[2894,2898],{"nctId":2870,"briefTitle":2871,"status":179,"phases":2895,"primaryCompletion":2873,"completion":2873,"start":2874,"enrollment":16,"conditions":2896,"interventions":2897},[85,86],[2876],[2878,2879,2849],{"nctId":2899,"briefTitle":2900,"status":179,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2214,"conditions":2904,"interventions":2908},"NCT04782856","Energy Metabolism in Thyroidectomized Patients",[86],"2023-04-19","2020-10-28",[2905,2906,2907],"Thyroid Goiter","Hypothyroidism","Thyroid Cancer",[2879,2878],{"trials":2910,"activeCount":97},[],{"trials":2912,"activeCount":97},[],{"trials":2914,"activeCount":97},[],{"intervention":2879,"totalTrials":319,"cells":2916},{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2918,"activeCount":97},[],{"trials":2920,"activeCount":97},[],{"trials":2922,"activeCount":97},[2923,2927],{"nctId":2870,"briefTitle":2871,"status":179,"phases":2924,"primaryCompletion":2873,"completion":2873,"start":2874,"enrollment":16,"conditions":2925,"interventions":2926},[85,86],[2876],[2878,2879,2849],{"nctId":2899,"briefTitle":2900,"status":179,"phases":2928,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2214,"conditions":2929,"interventions":2930},[86],[2905,2906,2907],[2879,2878],{"trials":2932,"activeCount":97},[],{"trials":2934,"activeCount":97},[],{"trials":2936,"activeCount":97},[],{"intervention":2938,"totalTrials":319,"cells":2939},"Sildenafil Citrate",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2955,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2941,"activeCount":97},[],{"trials":2943,"activeCount":97},[2944],{"nctId":2945,"briefTitle":2946,"status":179,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2950,"conditions":2951,"interventions":2953},"NCT02466802","Study of Regorafenib and Sildenafil for Advanced Solid Tumors",[85],"2019-01-28","2015-07-01",32,[2952],"Solid Tumor",[2954,2938],"Regorafenib",{"trials":2956,"activeCount":97},[2957],{"nctId":2712,"briefTitle":2713,"status":179,"phases":2958,"primaryCompletion":2715,"completion":2716,"start":2717,"enrollment":1831,"conditions":2959,"interventions":2960},[86],[2719,2720,2721,2722],[2680,2724,2725],{"trials":2962,"activeCount":97},[],{"trials":2964,"activeCount":97},[],{"trials":2966,"activeCount":97},[],{"intervention":2968,"totalTrials":319,"cells":2969},"Vitamin C",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2995,"PHASE4":2997,"NA":2999},{"trials":2971,"activeCount":97},[],{"trials":2973,"activeCount":97},[],{"trials":2975,"activeCount":97},[2976,2987],{"nctId":2977,"briefTitle":2978,"status":179,"phases":2979,"primaryCompletion":2980,"completion":2981,"start":2982,"enrollment":19,"conditions":2983,"interventions":2985},"NCT03829683","Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis",[86],"2022-03-31","2022-06-23","2019-04-16",[2984,2534],"Alcoholic Hepatitis",[2968,2986],"Dextrose 5% in water",{"nctId":2988,"briefTitle":2989,"status":179,"phases":2990,"primaryCompletion":2811,"completion":2811,"start":2991,"enrollment":19,"conditions":2992,"interventions":2994},"NCT03148236","Vitamin C in Atrial Fibrillation Ablation",[86],"2017-09-18",[2993],"Atrial Fibrillation Ablation",[2968],{"trials":2996,"activeCount":97},[],{"trials":2998,"activeCount":97},[],{"trials":3000,"activeCount":97},[],{"intervention":3002,"totalTrials":319,"cells":3003},"Perampanel",{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3005,"activeCount":97},[],{"trials":3007,"activeCount":97},[],{"trials":3009,"activeCount":97},[3010,3019],{"nctId":3011,"briefTitle":3012,"status":179,"phases":3013,"primaryCompletion":3014,"completion":3015,"start":3016,"enrollment":16,"conditions":3017,"interventions":3018},"NCT02120365","Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence",[85,86],"2022-02-15","2022-02-16","2019-06-01",[2002],[3002],{"nctId":3020,"briefTitle":3021,"status":179,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":477,"conditions":3025,"interventions":3027},"NCT04502589","Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder",[85,86],"2021-08-11","2020-10-15",[3026],"Alcohol Disorders",[3002,3028],"Disulfiram",{"trials":3030,"activeCount":97},[],{"trials":3032,"activeCount":97},[],{"trials":3034,"activeCount":97},[],{"intervention":2160,"totalTrials":319,"cells":3036},{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3041,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3038,"activeCount":97},[],{"trials":3040,"activeCount":97},[],{"trials":3042,"activeCount":97},[3043,3047],{"nctId":2138,"briefTitle":2139,"status":179,"phases":3044,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":273,"conditions":3045,"interventions":3046},[86],[2144,2145,31,21,2146,2147,2148,2149,2150,2151,361,2152,2153,2154,2155,2156,2157,2158],[2160,2161,2129],{"nctId":3048,"briefTitle":3049,"status":179,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":11,"conditions":3054,"interventions":3058},"NCT00709592","Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT",[86],"2014-02-15","2017-06-28","2008-07-21",[3055,21,2150,115,3056,2149,2151,3057],"Non-Hodgkin's Lymphoma","Hodgkin Lymphoma","Myelodysplastic Syndrome",[3059,3060,3061],"Thymoglobulin","Tacrolimus","Mycophenolate Mofetil",{"trials":3063,"activeCount":97},[],{"trials":3065,"activeCount":97},[],{"trials":3067,"activeCount":97},[],{"intervention":3069,"totalTrials":319,"cells":3070},"lovastatin",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3072,"activeCount":97},[],{"trials":3074,"activeCount":97},[],{"trials":3076,"activeCount":97},[3077,3086],{"nctId":3078,"briefTitle":3079,"status":179,"phases":3080,"primaryCompletion":3081,"completion":3081,"start":2457,"enrollment":3082,"conditions":3083,"interventions":3085},"NCT00580970","Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury",[86],"2015-08",73,[3084],"Prostate Cancer",[3069],{"nctId":3087,"briefTitle":3088,"status":228,"phases":3089,"primaryCompletion":3090,"completion":1882,"start":3091,"enrollment":1292,"conditions":3092,"interventions":3094},"NCT00902668","Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer",[86],"2011-04","2009-04",[18,3093],"Radiation Toxicity",[3069],{"trials":3096,"activeCount":97},[],{"trials":3098,"activeCount":97},[],{"trials":3100,"activeCount":97},[],{"intervention":3102,"totalTrials":93,"cells":3103},"Venetoclax 50 MG",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3127,"PHASE4":3129,"NA":3131},{"trials":3105,"activeCount":97},[],{"trials":3107,"activeCount":97},[],{"trials":3109,"activeCount":97},[3110],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3113,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3117,"interventions":3120},"NCT04543916","Venetoclax and Irinotecan in Relapsed\u002FRefractory SCLC",[85,86],"2028-05-30","2028-06-30","2021-06-30",[3118,3119],"Relapsed Small Cell Lung Cancer","Refractory Small Cell Lung Carcinoma",[3102,3121,3122,3123,3124,3125,3126],"Venetoclax 100 MG","Venetoclax 200 MG","Venetoclax 400","Venetoclax 600","Irinotecan 60 mg\u002Fm2","Venetoclax",{"trials":3128,"activeCount":97},[],{"trials":3130,"activeCount":97},[],{"trials":3132,"activeCount":97},[],{"intervention":3121,"totalTrials":93,"cells":3134},{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3139,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[],{"trials":3140,"activeCount":97},[3141],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3142,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3143,"interventions":3144},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3146,"activeCount":97},[],{"trials":3148,"activeCount":97},[],{"trials":3150,"activeCount":97},[],{"intervention":3122,"totalTrials":93,"cells":3152},{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3163,"PHASE4":3165,"NA":3167},{"trials":3154,"activeCount":97},[],{"trials":3156,"activeCount":97},[],{"trials":3158,"activeCount":97},[3159],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3160,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3161,"interventions":3162},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3164,"activeCount":97},[],{"trials":3166,"activeCount":97},[],{"trials":3168,"activeCount":97},[],{"intervention":3123,"totalTrials":93,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3181,"PHASE4":3183,"NA":3185},{"trials":3172,"activeCount":97},[],{"trials":3174,"activeCount":97},[],{"trials":3176,"activeCount":97},[3177],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3178,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3179,"interventions":3180},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3182,"activeCount":97},[],{"trials":3184,"activeCount":97},[],{"trials":3186,"activeCount":97},[],{"intervention":3124,"totalTrials":93,"cells":3188},{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3190,"activeCount":97},[],{"trials":3192,"activeCount":97},[],{"trials":3194,"activeCount":97},[3195],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3196,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3197,"interventions":3198},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3200,"activeCount":97},[],{"trials":3202,"activeCount":97},[],{"trials":3204,"activeCount":97},[],{"intervention":3125,"totalTrials":93,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3208,"activeCount":97},[],{"trials":3210,"activeCount":97},[],{"trials":3212,"activeCount":97},[3213],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3214,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3215,"interventions":3216},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3218,"activeCount":97},[],{"trials":3220,"activeCount":97},[],{"trials":3222,"activeCount":97},[],{"intervention":3126,"totalTrials":93,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3226,"activeCount":97},[],{"trials":3228,"activeCount":97},[],{"trials":3230,"activeCount":97},[3231],{"nctId":3111,"briefTitle":3112,"status":207,"phases":3232,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":97,"conditions":3233,"interventions":3234},[85,86],[3118,3119],[3102,3121,3122,3123,3124,3125,3126],{"trials":3236,"activeCount":97},[],{"trials":3238,"activeCount":97},[],{"trials":3240,"activeCount":97},[],{"intervention":3242,"totalTrials":93,"cells":3243},"Allopurinol",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3259,"PHASE4":3261,"NA":3263},{"trials":3245,"activeCount":97},[],{"trials":3247,"activeCount":97},[],{"trials":3249,"activeCount":97},[3250],{"nctId":3251,"briefTitle":3252,"status":228,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":3255,"enrollment":252,"conditions":3256,"interventions":3258},"NCT03865407","Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease",[86],"2020-10-07","2019-03-10",[3257,214],"Hyperuricemia",[3242],{"trials":3260,"activeCount":97},[],{"trials":3262,"activeCount":97},[],{"trials":3264,"activeCount":97},[],{"intervention":3266,"totalTrials":93,"cells":3267},"Doxycycline",{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3284,"PHASE4":3286,"NA":3288},{"trials":3269,"activeCount":97},[],{"trials":3271,"activeCount":97},[],{"trials":3273,"activeCount":97},[3274],{"nctId":3275,"briefTitle":3276,"status":228,"phases":3277,"primaryCompletion":3278,"completion":3278,"start":3279,"enrollment":294,"conditions":3280,"interventions":3283},"NCT01935622","Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy",[86],"2014-06","2012-07",[3281,3282],"Non-ischemic Cardiomyopathy","Systolic Heart Failure (NYHA II-III)",[3266],{"trials":3285,"activeCount":97},[],{"trials":3287,"activeCount":97},[],{"trials":3289,"activeCount":97},[],{"intervention":3291,"totalTrials":93,"cells":3292},"Experimental Arm A: Pemetrexed",{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3312,"PHASE4":3314,"NA":3316},{"trials":3294,"activeCount":97},[],{"trials":3296,"activeCount":97},[],{"trials":3298,"activeCount":97},[3299],{"nctId":3300,"briefTitle":3301,"status":228,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":2214,"conditions":3305,"interventions":3308},"NCT02624700","2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer",[86],"2019-07-10","2016-01-28",[18,3306,3307],"Metastatic Breast Cancer","Recurrent Breast Cancer",[3291,3309,3310,3311],"Experimental Arm A: Sorafenib","Experimental Arm B: Pemetrexed","Experimental Arm B: Sorafenib",{"trials":3313,"activeCount":97},[],{"trials":3315,"activeCount":97},[],{"trials":3317,"activeCount":97},[],{"intervention":3309,"totalTrials":93,"cells":3319},{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3330,"PHASE4":3332,"NA":3334},{"trials":3321,"activeCount":97},[],{"trials":3323,"activeCount":97},[],{"trials":3325,"activeCount":97},[3326],{"nctId":3300,"briefTitle":3301,"status":228,"phases":3327,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":2214,"conditions":3328,"interventions":3329},[86],[18,3306,3307],[3291,3309,3310,3311],{"trials":3331,"activeCount":97},[],{"trials":3333,"activeCount":97},[],{"trials":3335,"activeCount":97},[],{"intervention":3310,"totalTrials":93,"cells":3337},{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3342,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3339,"activeCount":97},[],{"trials":3341,"activeCount":97},[],{"trials":3343,"activeCount":97},[3344],{"nctId":3300,"briefTitle":3301,"status":228,"phases":3345,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":2214,"conditions":3346,"interventions":3347},[86],[18,3306,3307],[3291,3309,3310,3311],{"trials":3349,"activeCount":97},[],{"trials":3351,"activeCount":97},[],{"trials":3353,"activeCount":97},[],{"intervention":3311,"totalTrials":93,"cells":3355},{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3357,"activeCount":97},[],{"trials":3359,"activeCount":97},[],{"trials":3361,"activeCount":97},[3362],{"nctId":3300,"briefTitle":3301,"status":228,"phases":3363,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":2214,"conditions":3364,"interventions":3365},[86],[18,3306,3307],[3291,3309,3310,3311],{"trials":3367,"activeCount":97},[],{"trials":3369,"activeCount":97},[],{"trials":3371,"activeCount":97},[],{"intervention":2868,"totalTrials":93,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3375,"activeCount":97},[],{"trials":3377,"activeCount":97},[],{"trials":3379,"activeCount":97},[3380],{"nctId":2858,"briefTitle":2859,"status":179,"phases":3381,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":319,"conditions":3382,"interventions":3383},[86],[2864,2865,2866],[2868,2849],{"trials":3385,"activeCount":97},[],{"trials":3387,"activeCount":97},[],{"trials":3389,"activeCount":97},[],{"intervention":3391,"totalTrials":93,"cells":3392},"topiramate",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3394,"activeCount":97},[],{"trials":3396,"activeCount":97},[],{"trials":3398,"activeCount":97},[3399],{"nctId":3400,"briefTitle":3401,"status":179,"phases":3402,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":3405,"conditions":3406,"interventions":3408},"NCT02878798","Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)",[86],"2021-09-28","2018-02-12",132,[3407],"Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome",[3391],{"trials":3410,"activeCount":97},[],{"trials":3412,"activeCount":97},[],{"trials":3414,"activeCount":97},[],{"intervention":3416,"totalTrials":93,"cells":3417},"Citalopram",{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3432,"PHASE4":3434,"NA":3436},{"trials":3419,"activeCount":97},[],{"trials":3421,"activeCount":97},[],{"trials":3423,"activeCount":97},[3424],{"nctId":3425,"briefTitle":3426,"status":179,"phases":3427,"primaryCompletion":3428,"completion":3428,"start":3429,"enrollment":810,"conditions":3430,"interventions":3431},"NCT02080832","Brain Function and Structure in Cocaine Dependence",[86],"2016-02","2010-02",[2485],[3416],{"trials":3433,"activeCount":97},[],{"trials":3435,"activeCount":97},[],{"trials":3437,"activeCount":97},[],{"intervention":3439,"totalTrials":93,"cells":3440},"Alpha 1-Antitrypsin",{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3442,"activeCount":97},[],{"trials":3444,"activeCount":97},[],{"trials":3446,"activeCount":97},[3447],{"nctId":3448,"briefTitle":3449,"status":179,"phases":3450,"primaryCompletion":3278,"completion":3451,"start":3452,"enrollment":294,"conditions":3453,"interventions":3454},"NCT01936896","Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction",[85,86],"2014-07","2013-12",[244],[3439],{"trials":3456,"activeCount":97},[],{"trials":3458,"activeCount":97},[],{"trials":3460,"activeCount":97},[],{"intervention":3462,"totalTrials":93,"cells":3463},"N-acetyl-l-cysteine",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3479,"PHASE4":3481,"NA":3483},{"trials":3465,"activeCount":97},[],{"trials":3467,"activeCount":97},[],{"trials":3469,"activeCount":97},[3470],{"nctId":3471,"briefTitle":3472,"status":179,"phases":3473,"primaryCompletion":1856,"completion":3474,"start":3475,"enrollment":222,"conditions":3476,"interventions":3478},"NCT01840345","The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain",[86],"2017-04-01","2014-01",[3477],"Neuropathic Pain",[3462],{"trials":3480,"activeCount":97},[],{"trials":3482,"activeCount":97},[],{"trials":3484,"activeCount":97},[],{"intervention":3486,"totalTrials":93,"cells":3487},"Caffeine 150 MG",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3489,"activeCount":97},[],{"trials":3491,"activeCount":97},[],{"trials":3493,"activeCount":97},[3494],{"nctId":3495,"briefTitle":3496,"status":179,"phases":3497,"primaryCompletion":3498,"completion":2691,"start":3499,"enrollment":3500,"conditions":3501,"interventions":3502},"NCT00733993","Caffeine and Cocaine",[85,86],"2011-07","2008-04",23,[2485],[3486,3503,3504],"Amphetamine","Caffeine 300 MG",{"trials":3506,"activeCount":97},[],{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[],{"intervention":3503,"totalTrials":93,"cells":3512},{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3514,"activeCount":97},[],{"trials":3516,"activeCount":97},[],{"trials":3518,"activeCount":97},[3519],{"nctId":3495,"briefTitle":3496,"status":179,"phases":3520,"primaryCompletion":3498,"completion":2691,"start":3499,"enrollment":3500,"conditions":3521,"interventions":3522},[85,86],[2485],[3486,3503,3504],{"trials":3524,"activeCount":97},[],{"trials":3526,"activeCount":97},[],{"trials":3528,"activeCount":97},[],{"intervention":3504,"totalTrials":93,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3532,"activeCount":97},[],{"trials":3534,"activeCount":97},[],{"trials":3536,"activeCount":97},[3537],{"nctId":3495,"briefTitle":3496,"status":179,"phases":3538,"primaryCompletion":3498,"completion":2691,"start":3499,"enrollment":3500,"conditions":3539,"interventions":3540},[85,86],[2485],[3486,3503,3504],{"trials":3542,"activeCount":97},[],{"trials":3544,"activeCount":97},[],{"trials":3546,"activeCount":97},[],{"intervention":2986,"totalTrials":93,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3550,"activeCount":97},[],{"trials":3552,"activeCount":97},[],{"trials":3554,"activeCount":97},[3555],{"nctId":2977,"briefTitle":2978,"status":179,"phases":3556,"primaryCompletion":2980,"completion":2981,"start":2982,"enrollment":19,"conditions":3557,"interventions":3558},[86],[2984,2534],[2968,2986],{"trials":3560,"activeCount":97},[],{"trials":3562,"activeCount":97},[],{"trials":3564,"activeCount":97},[],{"intervention":3566,"totalTrials":93,"cells":3567},"levodopa\u002Fcarbidopa 400\u002F100 BID",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3582,"PHASE4":3584,"NA":3586},{"trials":3569,"activeCount":97},[],{"trials":3571,"activeCount":97},[],{"trials":3573,"activeCount":97},[3574],{"nctId":3575,"briefTitle":3576,"status":179,"phases":3577,"primaryCompletion":3578,"completion":3578,"start":284,"enrollment":3579,"conditions":3580,"interventions":3581},"NCT02080819","Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse",[86],"2017-01-21",131,[2485],[3566],{"trials":3583,"activeCount":97},[],{"trials":3585,"activeCount":97},[],{"trials":3587,"activeCount":97},[],{"intervention":483,"totalTrials":93,"cells":3589},{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3600,"PHASE4":3602,"NA":3604},{"trials":3591,"activeCount":97},[],{"trials":3593,"activeCount":97},[],{"trials":3595,"activeCount":97},[3596],{"nctId":471,"briefTitle":472,"status":228,"phases":3597,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":3598,"interventions":3599},[86],[479,480,481],[483,350],{"trials":3601,"activeCount":97},[],{"trials":3603,"activeCount":97},[],{"trials":3605,"activeCount":97},[],{"intervention":3607,"totalTrials":93,"cells":3608},"Lemborexant",{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3610,"activeCount":97},[],{"trials":3612,"activeCount":97},[],{"trials":3614,"activeCount":97},[3615],{"nctId":3616,"briefTitle":3617,"status":179,"phases":3618,"primaryCompletion":3619,"completion":3619,"start":3620,"enrollment":881,"conditions":3621,"interventions":3624},"NCT04818086","Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine\u002FNaloxone for Opioid Use Disorder",[85,86],"2023-04-20","2021-05-03",[3622,3623,532],"Drug Interaction","Analgesics",[3607,3625],"Buprenorphine-naloxone",{"trials":3627,"activeCount":97},[],{"trials":3629,"activeCount":97},[],{"trials":3631,"activeCount":97},[],{"intervention":3625,"totalTrials":93,"cells":3633},{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3635,"activeCount":97},[],{"trials":3637,"activeCount":97},[],{"trials":3639,"activeCount":97},[3640],{"nctId":3616,"briefTitle":3617,"status":179,"phases":3641,"primaryCompletion":3619,"completion":3619,"start":3620,"enrollment":881,"conditions":3642,"interventions":3643},[85,86],[3622,3623,532],[3607,3625],{"trials":3645,"activeCount":97},[],{"trials":3647,"activeCount":97},[],{"trials":3649,"activeCount":97},[],{"intervention":3651,"totalTrials":93,"cells":3652},"Mirtazapine 15 MG Oral",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3654,"activeCount":97},[],{"trials":3656,"activeCount":97},[],{"trials":3658,"activeCount":97},[3659],{"nctId":3660,"briefTitle":3661,"status":179,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":3665,"conditions":3666,"interventions":3667},"NCT03921151","5HT2CR Balance in Brain Connectivity in Cocaine Dependence",[85,86],"2019-01-24","2014-05-13",90,[2485],[3651],{"trials":3669,"activeCount":97},[],{"trials":3671,"activeCount":97},[],{"trials":3673,"activeCount":97},[],{"intervention":3675,"totalTrials":93,"cells":3676},"L-ascorbic acid",{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3678,"activeCount":97},[],{"trials":3680,"activeCount":97},[],{"trials":3682,"activeCount":97},[3683],{"nctId":3684,"briefTitle":3685,"status":179,"phases":3686,"primaryCompletion":3687,"completion":3687,"start":3688,"enrollment":1831,"conditions":3689,"interventions":3692},"NCT04344184","SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)",[86],"2022-06-10","2020-12-18",[2864,3690,3691],"Lung Injury, Acute","Kidney Injury",[3675],{"trials":3694,"activeCount":97},[],{"trials":3696,"activeCount":97},[],{"trials":3698,"activeCount":97},[],{"intervention":3700,"totalTrials":93,"cells":3701},"Anakinra 100 mg subcutaneously daily",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3703,"activeCount":97},[],{"trials":3705,"activeCount":97},[],{"trials":3707,"activeCount":97},[3708],{"nctId":3709,"briefTitle":3710,"status":228,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":1830,"enrollment":319,"conditions":3713,"interventions":3715},"NCT01479010","Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension",[85,86],"2013-11",[3714],"Pulmonary Hypertension",[3700],{"trials":3717,"activeCount":97},[],{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[],{"intervention":3723,"totalTrials":93,"cells":3724},"Nicotine Transdermal Patch",{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3729,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3726,"activeCount":97},[],{"trials":3728,"activeCount":97},[],{"trials":3730,"activeCount":97},[3731],{"nctId":3732,"briefTitle":3733,"status":228,"phases":3734,"primaryCompletion":3735,"completion":3735,"start":3736,"enrollment":477,"conditions":3737,"interventions":3741},"NCT04468230","Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy",[86],"2022-05-31","2020-07-31",[3738,3739,3477,3740],"Neuropathy","Peripheral Neuropathy","Chemotherapy-induced Peripheral Neuropathy",[3723],{"trials":3743,"activeCount":97},[],{"trials":3745,"activeCount":97},[],{"trials":3747,"activeCount":97},[],{"intervention":3749,"totalTrials":93,"cells":3750},"Ergocalciferol",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3752,"activeCount":97},[],{"trials":3754,"activeCount":97},[],{"trials":3756,"activeCount":97},[3757],{"nctId":3758,"briefTitle":3759,"status":3760,"phases":3761,"primaryCompletion":3762,"completion":3762,"start":3763,"enrollment":138,"conditions":3764,"interventions":3765},"NCT05259527","Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy","SUSPENDED",[86],"2030-03-31","2022-12-19",[3477],[3749],{"trials":3767,"activeCount":97},[],{"trials":3769,"activeCount":97},[],{"trials":3771,"activeCount":97},[],{"intervention":3773,"totalTrials":93,"cells":3774},"etanercept",{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3776,"activeCount":97},[],{"trials":3778,"activeCount":97},[],{"trials":3780,"activeCount":97},[3781],{"nctId":3782,"briefTitle":3783,"status":207,"phases":3784,"primaryCompletion":2690,"completion":3785,"start":220,"enrollment":97,"conditions":3786,"interventions":3788},"NCT00784966","Islet After Kidney Transplant for Type 1 Diabetes",[85,86],"2017-09",[3787],"Type 1 Diabetes Mellitus",[3773,3773],{"trials":3790,"activeCount":97},[],{"trials":3792,"activeCount":97},[],{"trials":3794,"activeCount":97},[],{"intervention":3796,"totalTrials":93,"cells":3797},"Carvedilol",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3799,"activeCount":97},[],{"trials":3801,"activeCount":97},[],{"trials":3803,"activeCount":97},[3804],{"nctId":3805,"briefTitle":3806,"status":179,"phases":3807,"primaryCompletion":1881,"completion":1881,"start":3808,"enrollment":294,"conditions":3809,"interventions":3810},"NCT00964678","Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension",[85,86],"2010-06",[185],[3796],{"trials":3812,"activeCount":97},[],{"trials":3814,"activeCount":97},[],{"trials":3816,"activeCount":97},[],{"intervention":3818,"totalTrials":93,"cells":3819},"Auvelity",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3821,"activeCount":97},[],{"trials":3823,"activeCount":97},[],{"trials":3825,"activeCount":97},[3826],{"nctId":3827,"briefTitle":3828,"status":179,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":3831,"enrollment":881,"conditions":3832,"interventions":3835},"NCT05976646","Phase Ib\u002F2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion",[85,86],"2025-07-09","2023-09-18",[3833,533,3834,532],"Addiction","Substance Use Disorders",[3818],{"trials":3837,"activeCount":97},[],{"trials":3839,"activeCount":97},[],{"trials":3841,"activeCount":97},[],{"intervention":3843,"totalTrials":93,"cells":3844},"R-pramipexole",{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3849,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3846,"activeCount":97},[],{"trials":3848,"activeCount":97},[],{"trials":3850,"activeCount":97},[3851],{"nctId":3852,"briefTitle":3853,"status":179,"phases":3854,"primaryCompletion":3475,"completion":2839,"start":3498,"enrollment":19,"conditions":3855,"interventions":3857},"NCT01388478","Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease",[86],[3856],"Alzheimer's Disease",[3843],{"trials":3859,"activeCount":97},[],{"trials":3861,"activeCount":97},[],{"trials":3863,"activeCount":97},[],{"intervention":3865,"totalTrials":93,"cells":3866},"Acetaminophen",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3884,"PHASE4":3886,"NA":3888},{"trials":3868,"activeCount":97},[],{"trials":3870,"activeCount":97},[],{"trials":3872,"activeCount":97},[3873],{"nctId":3874,"briefTitle":3875,"status":207,"phases":3876,"primaryCompletion":3877,"completion":3877,"start":3878,"enrollment":97,"conditions":3879,"interventions":3883},"NCT03947671","Active Temperature Management After Cardiac Surgery and Its Effect on Postoperative Cognitive Dysfunction",[86],"2026-10","2020-01-22",[3880,3881,3882],"Cardiac Surgery","Post-operative Cognitive Dysfunction","Fever",[3865],{"trials":3885,"activeCount":97},[],{"trials":3887,"activeCount":97},[],{"trials":3889,"activeCount":97},[],{"intervention":2161,"totalTrials":93,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3902,"PHASE4":3904,"NA":3906},{"trials":3893,"activeCount":97},[],{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[3898],{"nctId":2138,"briefTitle":2139,"status":179,"phases":3899,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":273,"conditions":3900,"interventions":3901},[86],[2144,2145,31,21,2146,2147,2148,2149,2150,2151,361,2152,2153,2154,2155,2156,2157,2158],[2160,2161,2129],{"trials":3903,"activeCount":97},[],{"trials":3905,"activeCount":97},[],{"trials":3907,"activeCount":97},[],{"intervention":3909,"totalTrials":93,"cells":3910},"Oral Aztreonam",{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3915,"PHASE3":3927,"PHASE4":3929,"NA":3931},{"trials":3912,"activeCount":97},[],{"trials":3914,"activeCount":97},[],{"trials":3916,"activeCount":97},[3917],{"nctId":3918,"briefTitle":3919,"status":228,"phases":3920,"primaryCompletion":3921,"completion":3921,"start":1487,"enrollment":232,"conditions":3922,"interventions":3924},"NCT02730793","Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease",[86],"2019-09-19",[3923],"Cystic Fibrosis",[3909,3925,3926],"Nasal Aztreonam","Nasal Placebo",{"trials":3928,"activeCount":97},[],{"trials":3930,"activeCount":97},[],{"trials":3932,"activeCount":97},[],{"intervention":3925,"totalTrials":93,"cells":3934},{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3939,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3936,"activeCount":97},[],{"trials":3938,"activeCount":97},[],{"trials":3940,"activeCount":97},[3941],{"nctId":3918,"briefTitle":3919,"status":228,"phases":3942,"primaryCompletion":3921,"completion":3921,"start":1487,"enrollment":232,"conditions":3943,"interventions":3944},[86],[3923],[3909,3925,3926],{"trials":3946,"activeCount":97},[],{"trials":3948,"activeCount":97},[],{"trials":3950,"activeCount":97},[],{"intervention":3926,"totalTrials":93,"cells":3952},{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3954,"activeCount":97},[],{"trials":3956,"activeCount":97},[],{"trials":3958,"activeCount":97},[3959],{"nctId":3918,"briefTitle":3919,"status":228,"phases":3960,"primaryCompletion":3921,"completion":3921,"start":1487,"enrollment":232,"conditions":3961,"interventions":3962},[86],[3923],[3909,3925,3926],{"trials":3964,"activeCount":97},[],{"trials":3966,"activeCount":97},[],{"trials":3968,"activeCount":97},[],{"intervention":3970,"totalTrials":93,"cells":3971},"ferumoxtran-10",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3985,"PHASE4":3987,"NA":3989},{"trials":3973,"activeCount":97},[],{"trials":3975,"activeCount":97},[],{"trials":3977,"activeCount":97},[3978],{"nctId":3979,"briefTitle":3980,"status":179,"phases":3981,"primaryCompletion":3982,"completion":3982,"start":2458,"enrollment":1292,"conditions":3983,"interventions":3984},"NCT00107484","Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer",[86],"2006-10",[18],[3970],{"trials":3986,"activeCount":97},[],{"trials":3988,"activeCount":97},[],{"trials":3990,"activeCount":97},[],{"intervention":3059,"totalTrials":93,"cells":3992},{"EARLY_PHASE1":3993,"PHASE1":3995,"PHASE2":3997,"PHASE3":4003,"PHASE4":4005,"NA":4007},{"trials":3994,"activeCount":97},[],{"trials":3996,"activeCount":97},[],{"trials":3998,"activeCount":97},[3999],{"nctId":3048,"briefTitle":3049,"status":179,"phases":4000,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":11,"conditions":4001,"interventions":4002},[86],[3055,21,2150,115,3056,2149,2151,3057],[3059,3060,3061],{"trials":4004,"activeCount":97},[],{"trials":4006,"activeCount":97},[],{"trials":4008,"activeCount":97},[],{"intervention":3060,"totalTrials":93,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4012,"activeCount":97},[],{"trials":4014,"activeCount":97},[],{"trials":4016,"activeCount":97},[4017],{"nctId":3048,"briefTitle":3049,"status":179,"phases":4018,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":11,"conditions":4019,"interventions":4020},[86],[3055,21,2150,115,3056,2149,2151,3057],[3059,3060,3061],{"trials":4022,"activeCount":97},[],{"trials":4024,"activeCount":97},[],{"trials":4026,"activeCount":97},[],{"intervention":4028,"totalTrials":93,"cells":4029},"Zoledronic Acid",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4044,"PHASE4":4046,"NA":4048},{"trials":4031,"activeCount":97},[],{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[4036],{"nctId":4037,"briefTitle":4038,"status":207,"phases":4039,"primaryCompletion":4040,"completion":4040,"start":2280,"enrollment":97,"conditions":4041,"interventions":4043},"NCT00639392","Phase 1 Study of Zoledronic Acid in Sickle Cell Disease",[85,86],"2008-05",[4042],"Sickle Cell Disease",[4028],{"trials":4045,"activeCount":97},[],{"trials":4047,"activeCount":97},[],{"trials":4049,"activeCount":97},[],{"intervention":4051,"totalTrials":93,"cells":4052},"Sodium Octanoate Breath Test",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4057,"PHASE3":4070,"PHASE4":4072,"NA":4074},{"trials":4054,"activeCount":97},[],{"trials":4056,"activeCount":97},[],{"trials":4058,"activeCount":97},[4059],{"nctId":4060,"briefTitle":4061,"status":228,"phases":4062,"primaryCompletion":4063,"completion":4064,"start":221,"enrollment":4065,"conditions":4066,"interventions":4069},"NCT01244503","Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)",[86],"2012-05","2012-06",61,[4067,4068],"Metabolic Syndrome","Nonalcoholic Fatty Liver Disease",[4051],{"trials":4071,"activeCount":97},[],{"trials":4073,"activeCount":97},[],{"trials":4075,"activeCount":97},[],{"intervention":4077,"totalTrials":93,"cells":4078},"Guaifenesin",{"EARLY_PHASE1":4079,"PHASE1":4081,"PHASE2":4083,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4080,"activeCount":97},[],{"trials":4082,"activeCount":97},[],{"trials":4084,"activeCount":97},[4085],{"nctId":4086,"briefTitle":4087,"status":179,"phases":4088,"primaryCompletion":4089,"completion":4089,"start":4090,"enrollment":160,"conditions":4091,"interventions":4093},"NCT01364467","The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study",[86],"2018-03-05","2011-05",[4092],"Chronic Rhinitis",[4077],{"trials":4095,"activeCount":97},[],{"trials":4097,"activeCount":97},[],{"trials":4099,"activeCount":97},[],{"intervention":4101,"totalTrials":93,"cells":4102},"5-azacytidine",{"EARLY_PHASE1":4103,"PHASE1":4105,"PHASE2":4107,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4104,"activeCount":97},[],{"trials":4106,"activeCount":97},[],{"trials":4108,"activeCount":97},[4109],{"nctId":4110,"briefTitle":4111,"status":179,"phases":4112,"primaryCompletion":3278,"completion":3278,"start":4113,"enrollment":2704,"conditions":4114,"interventions":4115},"NCT00721214","5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome",[86],"2008-07",[3057],[4101],{"trials":4117,"activeCount":97},[],{"trials":4119,"activeCount":97},[],{"trials":4121,"activeCount":97},[],{"intervention":4123,"totalTrials":93,"cells":4124},"Celecoxib",{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4129,"PHASE3":4138,"PHASE4":4140,"NA":4142},{"trials":4126,"activeCount":97},[],{"trials":4128,"activeCount":97},[],{"trials":4130,"activeCount":97},[4131],{"nctId":4132,"briefTitle":4133,"status":207,"phases":4134,"primaryCompletion":1804,"completion":1804,"start":1459,"enrollment":97,"conditions":4135,"interventions":4137},"NCT00442676","Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia",[86],[4136],"Preeclampsia",[4123],{"trials":4139,"activeCount":97},[],{"trials":4141,"activeCount":97},[],{"trials":4143,"activeCount":97},[],{"intervention":4145,"totalTrials":93,"cells":4146},"Intravenous (IV) and oral Vitamin C",{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4151,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4148,"activeCount":97},[],{"trials":4150,"activeCount":97},[],{"trials":4152,"activeCount":97},[4153],{"nctId":4154,"briefTitle":4155,"status":179,"phases":4156,"primaryCompletion":4157,"completion":4157,"start":1906,"enrollment":4065,"conditions":4158,"interventions":4162},"NCT03613727","Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients",[86],"2022-10-06",[2145,4159,4160,4161],"Myeloid Leukemia","Monocytic Leukemia","Myelodysplasia",[4145],{"trials":4164,"activeCount":97},[],{"trials":4166,"activeCount":97},[],{"trials":4168,"activeCount":97},[],{"intervention":4170,"totalTrials":93,"cells":4171},"Hepatocyte Transplantation",{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4173,"activeCount":97},[],{"trials":4175,"activeCount":97},[],{"trials":4177,"activeCount":97},[4178],{"nctId":4179,"briefTitle":4180,"status":207,"phases":4181,"primaryCompletion":2188,"completion":4182,"start":3278,"enrollment":97,"conditions":4183,"interventions":4185},"NCT00805610","Hepatocyte Transplantation in Liver Failure",[85,86],"2018-06",[4184],"Liver Failure",[4170],{"trials":4187,"activeCount":97},[],{"trials":4189,"activeCount":97},[],{"trials":4191,"activeCount":97},[],{"intervention":4193,"totalTrials":93,"cells":4194},"IMM 124-E",{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4211,"PHASE4":4213,"NA":4215},{"trials":4196,"activeCount":97},[],{"trials":4198,"activeCount":97},[],{"trials":4200,"activeCount":97},[4201],{"nctId":4202,"briefTitle":4203,"status":179,"phases":4204,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":4207,"conditions":4208,"interventions":4210},"NCT01968382","Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis",[86],"2018-12-22","2014-12",57,[4209],"Hepatitis, Alcoholic",[4193],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"trials":4216,"activeCount":97},[],{"intervention":3028,"totalTrials":93,"cells":4218},{"EARLY_PHASE1":4219,"PHASE1":4221,"PHASE2":4223,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4220,"activeCount":97},[],{"trials":4222,"activeCount":97},[],{"trials":4224,"activeCount":97},[4225],{"nctId":3020,"briefTitle":3021,"status":179,"phases":4226,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":477,"conditions":4227,"interventions":4228},[85,86],[3026],[3002,3028],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"intervention":2724,"totalTrials":93,"cells":4236},{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4241,"PHASE3":4247,"PHASE4":4249,"NA":4251},{"trials":4238,"activeCount":97},[],{"trials":4240,"activeCount":97},[],{"trials":4242,"activeCount":97},[4243],{"nctId":2712,"briefTitle":2713,"status":179,"phases":4244,"primaryCompletion":2715,"completion":2716,"start":2717,"enrollment":1831,"conditions":4245,"interventions":4246},[86],[2719,2720,2721,2722],[2680,2724,2725],{"trials":4248,"activeCount":97},[],{"trials":4250,"activeCount":97},[],{"trials":4252,"activeCount":97},[],{"intervention":4254,"totalTrials":93,"cells":4255},"magnesium oxide",{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4260,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4257,"activeCount":97},[],{"trials":4259,"activeCount":97},[],{"trials":4261,"activeCount":97},[4262],{"nctId":4263,"briefTitle":4264,"status":179,"phases":4265,"primaryCompletion":4266,"completion":4267,"start":2213,"enrollment":273,"conditions":4268,"interventions":4272},"NCT01008904","Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer",[86],"2013-01","2013-03",[18,4269,4270,4271],"Cancer Survivor","Hot Flashes","Unspecified Adult Solid Tumor, Protocol Specific",[4254],{"trials":4274,"activeCount":97},[],{"trials":4276,"activeCount":97},[],{"trials":4278,"activeCount":97},[],{"intervention":4280,"totalTrials":93,"cells":4281},"Istradefylline medication",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4283,"activeCount":97},[],{"trials":4285,"activeCount":97},[],{"trials":4287,"activeCount":97},[4288],{"nctId":4289,"briefTitle":4290,"status":179,"phases":4291,"primaryCompletion":4292,"completion":4292,"start":4293,"enrollment":1194,"conditions":4294,"interventions":4297},"NCT05333549","Istradefylline for Parkinson Disease With Cognitive Impairment",[86],"2025-06-09","2022-07-18",[4295,4296],"Parkinson Disease","Cognitive Impairment",[4280],{"trials":4299,"activeCount":97},[],{"trials":4301,"activeCount":97},[],{"trials":4303,"activeCount":97},[],{"intervention":2708,"totalTrials":319,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4307,"activeCount":97},[],{"trials":4309,"activeCount":97},[4310,4314],{"nctId":2698,"briefTitle":2699,"status":179,"phases":4311,"primaryCompletion":2701,"completion":2702,"start":2703,"enrollment":2704,"conditions":4312,"interventions":4313},[85],[2706],[2680,2708],{"nctId":4315,"briefTitle":4316,"status":179,"phases":4317,"primaryCompletion":4318,"completion":4319,"start":4320,"enrollment":3500,"conditions":4321,"interventions":4329},"NCT02349867","Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine\u002FSorafenib\u002FVorinostat in Pancreatic Cancer",[85],"2020-05-13","2022-05-13","2015-01-29",[4322,4323,4324,4325,4326,4327,4328],"Pancreatic Adenocarcinoma","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Recurrent Pancreatic Carcinoma",[4330,4331,4332],"Gemcitabine","Sorafenib","Vorinostat",{"trials":4334,"activeCount":97},[],{"trials":4336,"activeCount":97},[],{"trials":4338,"activeCount":97},[],{"trials":4340,"activeCount":97},[],{"intervention":4342,"totalTrials":319,"cells":4343},"bortezomib",{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4345,"activeCount":97},[],{"trials":4347,"activeCount":97},[4348,4358],{"nctId":4349,"briefTitle":4350,"status":179,"phases":4351,"primaryCompletion":4352,"completion":4352,"start":2826,"enrollment":4353,"conditions":4354,"interventions":4355},"NCT01075425","Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome",[85],"2015-02",41,[2147,115,3057,2151],[4342,4356,4357],"belinostat","western blotting",{"nctId":4359,"briefTitle":4360,"status":179,"phases":4361,"primaryCompletion":4362,"completion":4363,"start":4364,"enrollment":881,"conditions":4365,"interventions":4366},"NCT00963274","Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[85],"2014-07-17","2018-04-13","2010-04-26",[21,31],[4367,4368],"Bortezomib","Romidepsin",{"trials":4370,"activeCount":97},[],{"trials":4372,"activeCount":97},[],{"trials":4374,"activeCount":97},[],{"trials":4376,"activeCount":97},[],{"intervention":4378,"totalTrials":319,"cells":4379},"Lorcaserin",{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4406,"PHASE3":4408,"PHASE4":4410,"NA":4412},{"trials":4381,"activeCount":97},[],{"trials":4383,"activeCount":97},[4384,4395],{"nctId":4385,"briefTitle":4386,"status":179,"phases":4387,"primaryCompletion":4388,"completion":4388,"start":4389,"enrollment":4390,"conditions":4391,"interventions":4393},"NCT02537873","Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder",[85],"2018-07-19","2015-07",29,[4392],"Cocaine Use Disorder",[4378,4394],"Cocaine Intravenous",{"nctId":4396,"briefTitle":4397,"status":179,"phases":4398,"primaryCompletion":4399,"completion":4399,"start":4400,"enrollment":2950,"conditions":4401,"interventions":4405},"NCT03143855","Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder",[85],"2019-04-05","2017-01-30",[4402,4403,4404,533],"Opioid Abuse","Opioid Dependence","Opioid-Related Disorders",[4378],{"trials":4407,"activeCount":97},[],{"trials":4409,"activeCount":97},[],{"trials":4411,"activeCount":97},[],{"trials":4413,"activeCount":97},[],{"intervention":2696,"totalTrials":93,"cells":4415},{"EARLY_PHASE1":4416,"PHASE1":4418,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4417,"activeCount":97},[],{"trials":4419,"activeCount":97},[4420],{"nctId":2687,"briefTitle":2688,"status":179,"phases":4421,"primaryCompletion":383,"completion":2690,"start":2691,"enrollment":2692,"conditions":4422,"interventions":4423},[85],[2694],[2680,2696],{"trials":4425,"activeCount":97},[],{"trials":4427,"activeCount":97},[],{"trials":4429,"activeCount":97},[],{"trials":4431,"activeCount":97},[],{"intervention":2653,"totalTrials":93,"cells":4433},{"EARLY_PHASE1":4434,"PHASE1":4436,"PHASE2":4442,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4435,"activeCount":97},[],{"trials":4437,"activeCount":97},[4438],{"nctId":2643,"briefTitle":2644,"status":179,"phases":4439,"primaryCompletion":2646,"completion":2647,"start":2648,"enrollment":252,"conditions":4440,"interventions":4441},[85],[2650,2651],[2653,2066],{"trials":4443,"activeCount":97},[],{"trials":4445,"activeCount":97},[],{"trials":4447,"activeCount":97},[],{"trials":4449,"activeCount":97},[],{"intervention":4451,"totalTrials":93,"cells":4452},"Intravenous fluids",{"EARLY_PHASE1":4453,"PHASE1":4455,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4454,"activeCount":97},[],{"trials":4456,"activeCount":97},[4457],{"nctId":4458,"briefTitle":4459,"status":179,"phases":4460,"primaryCompletion":4461,"completion":4462,"start":4463,"enrollment":294,"conditions":4464,"interventions":4469},"NCT03964259","Reduced IV Fluids to Improve Clearance of HDMTX in Children w\u002FLymphoma or Acute Lymphoblastic Leukemia",[85],"2022-12-07","2022-12-28","2019-10-02",[31,4465,4466,4467,4468],"Acute Lymphoblastic Leukemia","Pediatric Cancer","Pediatric ALL","Pediatric Lymphoma",[4451],{"trials":4471,"activeCount":97},[],{"trials":4473,"activeCount":97},[],{"trials":4475,"activeCount":97},[],{"trials":4477,"activeCount":97},[],{"intervention":4479,"totalTrials":93,"cells":4480},"Dimethyl Fumarate",{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4498,"PHASE3":4500,"PHASE4":4502,"NA":4504},{"trials":4482,"activeCount":97},[],{"trials":4484,"activeCount":97},[4485],{"nctId":4486,"briefTitle":4487,"status":179,"phases":4488,"primaryCompletion":4489,"completion":4490,"start":4491,"enrollment":22,"conditions":4492,"interventions":4496},"NCT02337426","Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[85],"2016-11-08","2017-11-09","2015-02-13",[4493,4494,4495],"Adult Brain Glioblastoma","Adult Giant Cell Glioblastoma","Adult Gliosarcoma",[4479,4497],"Temozolomide",{"trials":4499,"activeCount":97},[],{"trials":4501,"activeCount":97},[],{"trials":4503,"activeCount":97},[],{"trials":4505,"activeCount":97},[],{"intervention":4497,"totalTrials":93,"cells":4507},{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4509,"activeCount":97},[],{"trials":4511,"activeCount":97},[4512],{"nctId":4486,"briefTitle":4487,"status":179,"phases":4513,"primaryCompletion":4489,"completion":4490,"start":4491,"enrollment":22,"conditions":4514,"interventions":4515},[85],[4493,4494,4495],[4479,4497],{"trials":4517,"activeCount":97},[],{"trials":4519,"activeCount":97},[],{"trials":4521,"activeCount":97},[],{"trials":4523,"activeCount":97},[],{"intervention":4525,"totalTrials":93,"cells":4526},"Octreotide LAR Depot",{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4539,"PHASE3":4541,"PHASE4":4543,"NA":4545},{"trials":4528,"activeCount":97},[],{"trials":4530,"activeCount":97},[4531],{"nctId":4532,"briefTitle":4533,"status":179,"phases":4534,"primaryCompletion":4535,"completion":4535,"start":2481,"enrollment":294,"conditions":4536,"interventions":4538},"NCT01707225","Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)",[85],"2014-10",[4537],"Gastrointestinal Bleeding",[4525],{"trials":4540,"activeCount":97},[],{"trials":4542,"activeCount":97},[],{"trials":4544,"activeCount":97},[],{"trials":4546,"activeCount":97},[],{"intervention":4548,"totalTrials":93,"cells":4549},"Dose combination 1-1",{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4551,"activeCount":97},[],{"trials":4553,"activeCount":97},[4554],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4560,"interventions":4569},"NCT03639324","Rituximab, Idelalisib, and Venetoclax in Relapsed\u002FRefractory CLL\u002FSLL",[85],"2021-10-18","2020-10-02",[2149,4561,4562,4563,4564,4565,4566,4567,4568],"CLL","Relapsed CLL","Refractory Chronic Lymphocytic Leukemia","Relapsed Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","SLL","Relapsed Small Lymphocytic Lymphoma","Refractory Small Lymphocytic Lymphoma",[4548,4570,4571,4572,4573,4574],"dose combination 1-2","Dose combination 1-3","dose combination 1-4","Sub-Trial: Dose combination 2-1","Sub-Trial: Dose combination 2-2",{"trials":4576,"activeCount":97},[],{"trials":4578,"activeCount":97},[],{"trials":4580,"activeCount":97},[],{"trials":4582,"activeCount":97},[],{"intervention":4570,"totalTrials":93,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":97},[],{"trials":4588,"activeCount":97},[4589],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4590,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4591,"interventions":4592},[85],[2149,4561,4562,4563,4564,4565,4566,4567,4568],[4548,4570,4571,4572,4573,4574],{"trials":4594,"activeCount":97},[],{"trials":4596,"activeCount":97},[],{"trials":4598,"activeCount":97},[],{"trials":4600,"activeCount":97},[],{"intervention":4571,"totalTrials":93,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":97},[],{"trials":4606,"activeCount":97},[4607],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4608,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4609,"interventions":4610},[85],[2149,4561,4562,4563,4564,4565,4566,4567,4568],[4548,4570,4571,4572,4573,4574],{"trials":4612,"activeCount":97},[],{"trials":4614,"activeCount":97},[],{"trials":4616,"activeCount":97},[],{"trials":4618,"activeCount":97},[],{"intervention":4572,"totalTrials":93,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4635},{"trials":4622,"activeCount":97},[],{"trials":4624,"activeCount":97},[4625],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4626,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4627,"interventions":4628},[85],[2149,4561,4562,4563,4564,4565,4566,4567,4568],[4548,4570,4571,4572,4573,4574],{"trials":4630,"activeCount":97},[],{"trials":4632,"activeCount":97},[],{"trials":4634,"activeCount":97},[],{"trials":4636,"activeCount":97},[],{"intervention":4573,"totalTrials":93,"cells":4638},{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4640,"activeCount":97},[],{"trials":4642,"activeCount":97},[4643],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4644,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4645,"interventions":4646},[85],[2149,4561,4562,4563,4564,4565,4566,4567,4568],[4548,4570,4571,4572,4573,4574],{"trials":4648,"activeCount":97},[],{"trials":4650,"activeCount":97},[],{"trials":4652,"activeCount":97},[],{"trials":4654,"activeCount":97},[],{"intervention":4574,"totalTrials":93,"cells":4656},{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4658,"activeCount":97},[],{"trials":4660,"activeCount":97},[4661],{"nctId":4555,"briefTitle":4556,"status":207,"phases":4662,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":97,"conditions":4663,"interventions":4664},[85],[2149,4561,4562,4563,4564,4565,4566,4567,4568],[4548,4570,4571,4572,4573,4574],{"trials":4666,"activeCount":97},[],{"trials":4668,"activeCount":97},[],{"trials":4670,"activeCount":97},[],{"trials":4672,"activeCount":97},[],{"intervention":4674,"totalTrials":93,"cells":4675},"Brentuximab vedotin",{"EARLY_PHASE1":4676,"PHASE1":4678,"PHASE2":4690,"PHASE3":4692,"PHASE4":4694,"NA":4696},{"trials":4677,"activeCount":97},[],{"trials":4679,"activeCount":97},[4680],{"nctId":4681,"briefTitle":4682,"status":179,"phases":4683,"primaryCompletion":4684,"completion":4684,"start":4685,"enrollment":232,"conditions":4686,"interventions":4689},"NCT02822586","TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome",[85],"2019-04-29","2016-12-19",[4687,4688],"Mycosis Fungoides","Sézary Syndrome",[4674],{"trials":4691,"activeCount":97},[],{"trials":4693,"activeCount":97},[],{"trials":4695,"activeCount":97},[],{"trials":4697,"activeCount":97},[],{"intervention":2954,"totalTrials":93,"cells":4699},{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4708,"PHASE3":4710,"PHASE4":4712,"NA":4714},{"trials":4701,"activeCount":97},[],{"trials":4703,"activeCount":97},[4704],{"nctId":2945,"briefTitle":2946,"status":179,"phases":4705,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2950,"conditions":4706,"interventions":4707},[85],[2952],[2954,2938],{"trials":4709,"activeCount":97},[],{"trials":4711,"activeCount":97},[],{"trials":4713,"activeCount":97},[],{"trials":4715,"activeCount":97},[],{"intervention":449,"totalTrials":93,"cells":4717},{"EARLY_PHASE1":4718,"PHASE1":4720,"PHASE2":4726,"PHASE3":4728,"PHASE4":4730,"NA":4732},{"trials":4719,"activeCount":97},[],{"trials":4721,"activeCount":97},[4722],{"nctId":436,"briefTitle":437,"status":179,"phases":4723,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":4724,"interventions":4725},[85],[18,444,445,446,447],[39,449],{"trials":4727,"activeCount":97},[],{"trials":4729,"activeCount":97},[],{"trials":4731,"activeCount":97},[],{"trials":4733,"activeCount":97},[],{"intervention":4735,"totalTrials":93,"cells":4736},"FMT",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4738,"activeCount":97},[],{"trials":4740,"activeCount":97},[4741],{"nctId":4742,"briefTitle":4743,"status":179,"phases":4744,"primaryCompletion":4745,"completion":4745,"start":4746,"enrollment":19,"conditions":4747,"interventions":4750},"NCT03152188","Oral Fecal Transplant in Cirrhosis",[85],"2018-11-12","2017-06-12",[4748,4749],"Hepatic Encephalopathy","Cirrhosis, Liver",[4735],{"trials":4752,"activeCount":97},[],{"trials":4754,"activeCount":97},[],{"trials":4756,"activeCount":97},[],{"trials":4758,"activeCount":97},[],{"intervention":4760,"totalTrials":93,"cells":4761},"Lactobacillus GG",{"EARLY_PHASE1":4762,"PHASE1":4764,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4763,"activeCount":97},[],{"trials":4765,"activeCount":97},[4766],{"nctId":4767,"briefTitle":4768,"status":179,"phases":4769,"primaryCompletion":241,"completion":4267,"start":2279,"enrollment":2692,"conditions":4770,"interventions":4772},"NCT00992290","Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy",[85],[4771],"Minimal Hepatic Encephalopathy",[4760],{"trials":4774,"activeCount":97},[],{"trials":4776,"activeCount":97},[],{"trials":4778,"activeCount":97},[],{"trials":4780,"activeCount":97},[],{"intervention":4782,"totalTrials":93,"cells":4783},"Group A Lorcaserin",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4798,"PHASE3":4800,"PHASE4":4802,"NA":4804},{"trials":4785,"activeCount":97},[],{"trials":4787,"activeCount":97},[4788],{"nctId":4789,"briefTitle":4790,"status":228,"phases":4791,"primaryCompletion":4792,"completion":4792,"start":4389,"enrollment":4793,"conditions":4794,"interventions":4796},"NCT03143543","Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder",[85],"2019-12-06",171,[4795,4404],"Cocaine-Related Disorders",[4782,4797],"Group A2 Lorcaserin",{"trials":4799,"activeCount":97},[],{"trials":4801,"activeCount":97},[],{"trials":4803,"activeCount":97},[],{"trials":4805,"activeCount":97},[],{"intervention":4797,"totalTrials":93,"cells":4807},{"EARLY_PHASE1":4808,"PHASE1":4810,"PHASE2":4816,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4809,"activeCount":97},[],{"trials":4811,"activeCount":97},[4812],{"nctId":4789,"briefTitle":4790,"status":228,"phases":4813,"primaryCompletion":4792,"completion":4792,"start":4389,"enrollment":4793,"conditions":4814,"interventions":4815},[85],[4795,4404],[4782,4797],{"trials":4817,"activeCount":97},[],{"trials":4819,"activeCount":97},[],{"trials":4821,"activeCount":97},[],{"trials":4823,"activeCount":97},[],{"intervention":4356,"totalTrials":93,"cells":4825},{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4834,"PHASE3":4836,"PHASE4":4838,"NA":4840},{"trials":4827,"activeCount":97},[],{"trials":4829,"activeCount":97},[4830],{"nctId":4349,"briefTitle":4350,"status":179,"phases":4831,"primaryCompletion":4352,"completion":4352,"start":2826,"enrollment":4353,"conditions":4832,"interventions":4833},[85],[2147,115,3057,2151],[4342,4356,4357],{"trials":4835,"activeCount":97},[],{"trials":4837,"activeCount":97},[],{"trials":4839,"activeCount":97},[],{"trials":4841,"activeCount":97},[],{"intervention":4357,"totalTrials":93,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4852,"PHASE3":4854,"PHASE4":4856,"NA":4858},{"trials":4845,"activeCount":97},[],{"trials":4847,"activeCount":97},[4848],{"nctId":4349,"briefTitle":4350,"status":179,"phases":4849,"primaryCompletion":4352,"completion":4352,"start":2826,"enrollment":4353,"conditions":4850,"interventions":4851},[85],[2147,115,3057,2151],[4342,4356,4357],{"trials":4853,"activeCount":97},[],{"trials":4855,"activeCount":97},[],{"trials":4857,"activeCount":97},[],{"trials":4859,"activeCount":97},[],{"intervention":4861,"totalTrials":93,"cells":4862},"Intrathecal hydromorphone",{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4876,"PHASE3":4878,"PHASE4":4880,"NA":4882},{"trials":4864,"activeCount":97},[],{"trials":4866,"activeCount":97},[4867],{"nctId":4868,"briefTitle":4869,"status":228,"phases":4870,"primaryCompletion":4871,"completion":4871,"start":182,"enrollment":170,"conditions":4872,"interventions":4875},"NCT02787928","Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System",[85],"2017-12-31",[4873,4874],"Cesarean Section","Obstetric Anesthesia",[4861],{"trials":4877,"activeCount":97},[],{"trials":4879,"activeCount":97},[],{"trials":4881,"activeCount":97},[],{"trials":4883,"activeCount":97},[],{"intervention":4885,"totalTrials":93,"cells":4886},"cisplatin",{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4915,"PHASE3":4917,"PHASE4":4919,"NA":4921},{"trials":4888,"activeCount":97},[],{"trials":4890,"activeCount":97},[4891],{"nctId":4892,"briefTitle":4893,"status":228,"phases":4894,"primaryCompletion":4895,"completion":4896,"start":3498,"enrollment":1292,"conditions":4897,"interventions":4914},"NCT01283178","Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC",[85],"2016-03","2016-09",[4898,4899,4900,4901,4902,4903,4904,4905,4906,4907,4908,4909,4910,4911,4912,4913],"Salivary Gland Squamous Cell Carcinoma","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Oral Cavity",[4885],{"trials":4916,"activeCount":97},[],{"trials":4918,"activeCount":97},[],{"trials":4920,"activeCount":97},[],{"trials":4922,"activeCount":97},[],{"intervention":4924,"totalTrials":93,"cells":4925},"Dacarbazine and bortezomib",{"EARLY_PHASE1":4926,"PHASE1":4928,"PHASE2":4941,"PHASE3":4943,"PHASE4":4945,"NA":4947},{"trials":4927,"activeCount":97},[],{"trials":4929,"activeCount":97},[4930],{"nctId":4931,"briefTitle":4932,"status":179,"phases":4933,"primaryCompletion":2279,"completion":3712,"start":2084,"enrollment":252,"conditions":4934,"interventions":4940},"NCT00580320","Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma",[85],[4935,4936,4937,4938,4939],"Melanoma","Soft Tissue Sarcoma","Parathyroid Carcinoma","Small Cell Carcinoma of the Lung","Carcinoid Tumors",[4924],{"trials":4942,"activeCount":97},[],{"trials":4944,"activeCount":97},[],{"trials":4946,"activeCount":97},[],{"trials":4948,"activeCount":97},[],{"intervention":2077,"totalTrials":93,"cells":4950},{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4959,"PHASE3":4961,"PHASE4":4963,"NA":4965},{"trials":4952,"activeCount":97},[],{"trials":4954,"activeCount":97},[4955],{"nctId":2068,"briefTitle":2069,"status":179,"phases":4956,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":1194,"conditions":4957,"interventions":4958},[85],[2074,21,31,2075],[366,2077],{"trials":4960,"activeCount":97},[],{"trials":4962,"activeCount":97},[],{"trials":4964,"activeCount":97},[],{"trials":4966,"activeCount":97},[],{"intervention":2666,"totalTrials":93,"cells":4968},{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":4977,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4970,"activeCount":97},[],{"trials":4972,"activeCount":97},[4973],{"nctId":2659,"briefTitle":2660,"status":179,"phases":4974,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":810,"conditions":4975,"interventions":4976},[85],[21,31],[2066,2666],{"trials":4978,"activeCount":97},[],{"trials":4980,"activeCount":97},[],{"trials":4982,"activeCount":97},[],{"trials":4984,"activeCount":97},[],{"intervention":1240,"totalTrials":93,"cells":4986},{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4995,"PHASE3":4997,"PHASE4":4999,"NA":5001},{"trials":4988,"activeCount":97},[],{"trials":4990,"activeCount":97},[4991],{"nctId":1232,"briefTitle":1233,"status":228,"phases":4992,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":477,"conditions":4993,"interventions":4994},[85],[1238],[1225,1240],{"trials":4996,"activeCount":97},[],{"trials":4998,"activeCount":97},[],{"trials":5000,"activeCount":97},[],{"trials":5002,"activeCount":97},[],{"intervention":5004,"totalTrials":93,"cells":5005},"AR-42",{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5022,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5007,"activeCount":97},[],{"trials":5009,"activeCount":97},[5010],{"nctId":5011,"briefTitle":5012,"status":228,"phases":5013,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":2813,"conditions":5017,"interventions":5020},"NCT02795819","Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer",[85],"2016-11-24","2019-03-14","2016-07-08",[5018,4936,5019],"Renal Cell Carcinoma","Metastatic Disease",[5004,5021],"Pazopanib",{"trials":5023,"activeCount":97},[],{"trials":5025,"activeCount":97},[],{"trials":5027,"activeCount":97},[],{"trials":5029,"activeCount":97},[],{"intervention":5021,"totalTrials":93,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5040,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":97},[],{"trials":5035,"activeCount":97},[5036],{"nctId":5011,"briefTitle":5012,"status":228,"phases":5037,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":2813,"conditions":5038,"interventions":5039},[85],[5018,4936,5019],[5004,5021],{"trials":5041,"activeCount":97},[],{"trials":5043,"activeCount":97},[],{"trials":5045,"activeCount":97},[],{"trials":5047,"activeCount":97},[],{"intervention":5049,"totalTrials":93,"cells":5050},"fluorouracil",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5052,"activeCount":97},[],{"trials":5054,"activeCount":97},[5055],{"nctId":5056,"briefTitle":5057,"status":179,"phases":5058,"primaryCompletion":5059,"completion":5060,"start":5061,"enrollment":170,"conditions":5062,"interventions":5073},"NCT02270606","Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer",[85],"2018-05-14","2021-05-13","2014-12-04",[5063,5064,5065,5066,5067,5068,5069,5070,5071,5072],"Mucinous Adenocarcinoma of the Rectum","Recurrent Rectal Cancer","Signet Ring Adenocarcinoma of the Rectum","Rectal Adenocarcinoma","Stage IIA Rectal Cancer","Stage IIB Rectal Cancer","Stage IIC Rectal Cancer","Stage IIIA Rectal Cancer","Stage IIIB Rectal Cancer","Stage IIIC Rectal Cancer",[5049,5074,5075],"oxaliplatin","leucovorin calcium",{"trials":5077,"activeCount":97},[],{"trials":5079,"activeCount":97},[],{"trials":5081,"activeCount":97},[],{"trials":5083,"activeCount":97},[],{"intervention":5074,"totalTrials":93,"cells":5085},{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5087,"activeCount":97},[],{"trials":5089,"activeCount":97},[5090],{"nctId":5056,"briefTitle":5057,"status":179,"phases":5091,"primaryCompletion":5059,"completion":5060,"start":5061,"enrollment":170,"conditions":5092,"interventions":5093},[85],[5063,5064,5065,5066,5067,5068,5069,5070,5071,5072],[5049,5074,5075],{"trials":5095,"activeCount":97},[],{"trials":5097,"activeCount":97},[],{"trials":5099,"activeCount":97},[],{"trials":5101,"activeCount":97},[],{"intervention":5075,"totalTrials":93,"cells":5103},{"EARLY_PHASE1":5104,"PHASE1":5106,"PHASE2":5112,"PHASE3":5114,"PHASE4":5116,"NA":5118},{"trials":5105,"activeCount":97},[],{"trials":5107,"activeCount":97},[5108],{"nctId":5056,"briefTitle":5057,"status":179,"phases":5109,"primaryCompletion":5059,"completion":5060,"start":5061,"enrollment":170,"conditions":5110,"interventions":5111},[85],[5063,5064,5065,5066,5067,5068,5069,5070,5071,5072],[5049,5074,5075],{"trials":5113,"activeCount":97},[],{"trials":5115,"activeCount":97},[],{"trials":5117,"activeCount":97},[],{"trials":5119,"activeCount":97},[],{"intervention":4330,"totalTrials":93,"cells":5121},{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5130,"PHASE3":5132,"PHASE4":5134,"NA":5136},{"trials":5123,"activeCount":97},[],{"trials":5125,"activeCount":97},[5126],{"nctId":4315,"briefTitle":4316,"status":179,"phases":5127,"primaryCompletion":4318,"completion":4319,"start":4320,"enrollment":3500,"conditions":5128,"interventions":5129},[85],[4322,4323,4324,4325,4326,4327,4328],[4330,4331,4332],{"trials":5131,"activeCount":97},[],{"trials":5133,"activeCount":97},[],{"trials":5135,"activeCount":97},[],{"trials":5137,"activeCount":97},[],{"intervention":4331,"totalTrials":93,"cells":5139},{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5148,"PHASE3":5150,"PHASE4":5152,"NA":5154},{"trials":5141,"activeCount":97},[],{"trials":5143,"activeCount":97},[5144],{"nctId":4315,"briefTitle":4316,"status":179,"phases":5145,"primaryCompletion":4318,"completion":4319,"start":4320,"enrollment":3500,"conditions":5146,"interventions":5147},[85],[4322,4323,4324,4325,4326,4327,4328],[4330,4331,4332],{"trials":5149,"activeCount":97},[],{"trials":5151,"activeCount":97},[],{"trials":5153,"activeCount":97},[],{"trials":5155,"activeCount":97},[],{"intervention":5157,"totalTrials":93,"cells":5158},"Treatment with liposomal bupivacaine",{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5174,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5160,"activeCount":97},[],{"trials":5162,"activeCount":97},[5163],{"nctId":5164,"briefTitle":5165,"status":179,"phases":5166,"primaryCompletion":5167,"completion":5167,"start":5168,"enrollment":25,"conditions":5169,"interventions":5172},"NCT06077214","Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients",[85],"2024-08-20","2023-01-31",[5170,5171],"Bariatric Surgery Candidate","Post-operative Pain",[5157,5173],"Treatment with standard bupivacaine",{"trials":5175,"activeCount":97},[],{"trials":5177,"activeCount":97},[],{"trials":5179,"activeCount":97},[],{"trials":5181,"activeCount":97},[],{"intervention":5173,"totalTrials":93,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5192,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5185,"activeCount":97},[],{"trials":5187,"activeCount":97},[5188],{"nctId":5164,"briefTitle":5165,"status":179,"phases":5189,"primaryCompletion":5167,"completion":5167,"start":5168,"enrollment":25,"conditions":5190,"interventions":5191},[85],[5170,5171],[5157,5173],{"trials":5193,"activeCount":97},[],{"trials":5195,"activeCount":97},[],{"trials":5197,"activeCount":97},[],{"trials":5199,"activeCount":97},[],{"intervention":4394,"totalTrials":93,"cells":5201},{"EARLY_PHASE1":5202,"PHASE1":5204,"PHASE2":5210,"PHASE3":5212,"PHASE4":5214,"NA":5216},{"trials":5203,"activeCount":97},[],{"trials":5205,"activeCount":97},[5206],{"nctId":4385,"briefTitle":4386,"status":179,"phases":5207,"primaryCompletion":4388,"completion":4388,"start":4389,"enrollment":4390,"conditions":5208,"interventions":5209},[85],[4392],[4378,4394],{"trials":5211,"activeCount":97},[],{"trials":5213,"activeCount":97},[],{"trials":5215,"activeCount":97},[],{"trials":5217,"activeCount":97},[],{"intervention":5219,"totalTrials":93,"cells":5220},"hydroxychloroquine",{"EARLY_PHASE1":5221,"PHASE1":5223,"PHASE2":5232,"PHASE3":5234,"PHASE4":5236,"NA":5238},{"trials":5222,"activeCount":97},[],{"trials":5224,"activeCount":97},[5225],{"nctId":5226,"briefTitle":5227,"status":228,"phases":5228,"primaryCompletion":3451,"completion":3451,"start":220,"enrollment":294,"conditions":5229,"interventions":5231},"NCT01417403","Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases",[85],[5230,4271],"Bone Metastases",[5219],{"trials":5233,"activeCount":97},[],{"trials":5235,"activeCount":97},[],{"trials":5237,"activeCount":97},[],{"trials":5239,"activeCount":97},[],{"intervention":4368,"totalTrials":93,"cells":5241},{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5250,"PHASE3":5252,"PHASE4":5254,"NA":5256},{"trials":5243,"activeCount":97},[],{"trials":5245,"activeCount":97},[5246],{"nctId":4359,"briefTitle":4360,"status":179,"phases":5247,"primaryCompletion":4362,"completion":4363,"start":4364,"enrollment":881,"conditions":5248,"interventions":5249},[85],[21,31],[4367,4368],{"trials":5251,"activeCount":97},[],{"trials":5253,"activeCount":97},[],{"trials":5255,"activeCount":97},[],{"trials":5257,"activeCount":97},[],{"intervention":5259,"totalTrials":93,"cells":5260},"RQ-00000010",{"EARLY_PHASE1":5261,"PHASE1":5263,"PHASE2":5276,"PHASE3":5278,"PHASE4":5280,"NA":5282},{"trials":5262,"activeCount":97},[],{"trials":5264,"activeCount":97},[5265],{"nctId":5266,"briefTitle":5267,"status":179,"phases":5268,"primaryCompletion":5269,"completion":5269,"start":2188,"enrollment":5270,"conditions":5271,"interventions":5275},"NCT02838797","RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease",[85],"2019-08-20",51,[5272,5273,5274],"Parkinson's Disease","Gastroparesis","Constipation",[5259],{"trials":5277,"activeCount":97},[],{"trials":5279,"activeCount":97},[],{"trials":5281,"activeCount":97},[],{"trials":5283,"activeCount":97},[],{"intervention":5285,"totalTrials":93,"cells":5286},"alvocidib",{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5299,"PHASE3":5301,"PHASE4":5303,"NA":5305},{"trials":5288,"activeCount":97},[],{"trials":5290,"activeCount":97},[5291],{"nctId":5292,"briefTitle":5293,"status":179,"phases":5294,"start":5295,"enrollment":16,"conditions":5296,"interventions":5297},"NCT00064285","Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer",[85],"2003-06",[21],[5285,5298],"imatinib mesylate",{"trials":5300,"activeCount":97},[],{"trials":5302,"activeCount":97},[],{"trials":5304,"activeCount":97},[],{"trials":5306,"activeCount":97},[],{"intervention":5298,"totalTrials":93,"cells":5308},{"EARLY_PHASE1":5309,"PHASE1":5311,"PHASE2":5317,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5310,"activeCount":97},[],{"trials":5312,"activeCount":97},[5313],{"nctId":5292,"briefTitle":5293,"status":179,"phases":5314,"start":5295,"enrollment":16,"conditions":5315,"interventions":5316},[85],[21],[5285,5298],{"trials":5318,"activeCount":97},[],{"trials":5320,"activeCount":97},[],{"trials":5322,"activeCount":97},[],{"trials":5324,"activeCount":97},[],{"intervention":5326,"totalTrials":93,"cells":5327},"CyMVectin",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5342,"PHASE3":5344,"PHASE4":5346,"NA":5348},{"trials":5329,"activeCount":97},[],{"trials":5331,"activeCount":97},[5332],{"nctId":5333,"briefTitle":5334,"status":207,"phases":5335,"primaryCompletion":5336,"completion":5337,"start":5338,"enrollment":97,"conditions":5339,"interventions":5341},"NCT02594566","Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine",[85],"2016-08","2017-02","2015-11",[5340],"Congenital Cytomegalovirus Infection",[5326],{"trials":5343,"activeCount":97},[],{"trials":5345,"activeCount":97},[],{"trials":5347,"activeCount":97},[],{"trials":5349,"activeCount":97},[],{"intervention":5351,"totalTrials":319,"cells":5352},"Resveratrol",{"EARLY_PHASE1":5353,"PHASE1":5374,"PHASE2":5376,"PHASE3":5378,"PHASE4":5380,"NA":5382},{"trials":5354,"activeCount":97},[5355,5364],{"nctId":5356,"briefTitle":5357,"status":179,"phases":5358,"primaryCompletion":5359,"completion":5360,"start":1513,"enrollment":442,"conditions":5361,"interventions":5363},"NCT03819517","Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease",[84],"2022-08-30","2023-08-30",[5362],"Chronic Obstructive Pulmonary Disease",[5351],{"nctId":5365,"briefTitle":5366,"status":179,"phases":5367,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":5370,"conditions":5371,"interventions":5372},"NCT04166396","Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis",[84],"2024-07-30","2020-02-17",8,[3923],[5351,5373],"NR",{"trials":5375,"activeCount":97},[],{"trials":5377,"activeCount":97},[],{"trials":5379,"activeCount":97},[],{"trials":5381,"activeCount":97},[],{"trials":5383,"activeCount":97},[],{"intervention":5385,"totalTrials":93,"cells":5386},"Buprenorphine",{"EARLY_PHASE1":5387,"PHASE1":5400,"PHASE2":5402,"PHASE3":5404,"PHASE4":5406,"NA":5408},{"trials":5388,"activeCount":97},[5389],{"nctId":5390,"briefTitle":5391,"status":179,"phases":5392,"primaryCompletion":5393,"completion":5393,"start":5394,"enrollment":1292,"conditions":5395,"interventions":5399},"NCT03489161","Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal",[84],"2018-08-28","2018-08-01",[5396,5397,5398],"Drug Overdose","Opioid Withdrawal","Opioid-use Disorder",[5385],{"trials":5401,"activeCount":97},[],{"trials":5403,"activeCount":97},[],{"trials":5405,"activeCount":97},[],{"trials":5407,"activeCount":97},[],{"trials":5409,"activeCount":97},[],{"intervention":5411,"totalTrials":93,"cells":5412},"Tobacco flavored liquid type 1",{"EARLY_PHASE1":5413,"PHASE1":5424,"PHASE2":5426,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5414,"activeCount":97},[5415],{"nctId":5416,"briefTitle":5417,"status":179,"phases":5418,"primaryCompletion":5368,"completion":5368,"start":5419,"enrollment":477,"conditions":5420,"interventions":5422},"NCT05199480","Understanding the Impact of Cartridge-Based Electronic Cigarettes and Generated Aerosols on Cardiopulmonary Health",[84],"2022-01-10",[5421],"E-Cig Use",[5411,5423],"Tobacco flavored liquid type 2",{"trials":5425,"activeCount":97},[],{"trials":5427,"activeCount":97},[],{"trials":5429,"activeCount":97},[],{"trials":5431,"activeCount":97},[],{"trials":5433,"activeCount":97},[],{"intervention":5423,"totalTrials":93,"cells":5435},{"EARLY_PHASE1":5436,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5437,"activeCount":97},[5438],{"nctId":5416,"briefTitle":5417,"status":179,"phases":5439,"primaryCompletion":5368,"completion":5368,"start":5419,"enrollment":477,"conditions":5440,"interventions":5441},[84],[5421],[5411,5423],{"trials":5443,"activeCount":97},[],{"trials":5445,"activeCount":97},[],{"trials":5447,"activeCount":97},[],{"trials":5449,"activeCount":97},[],{"trials":5451,"activeCount":97},[],{"intervention":5453,"totalTrials":93,"cells":5454},"SYN115",{"EARLY_PHASE1":5455,"PHASE1":5464,"PHASE2":5466,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5456,"activeCount":97},[5457],{"nctId":5458,"briefTitle":5459,"status":179,"phases":5460,"primaryCompletion":4266,"completion":4266,"start":5461,"enrollment":442,"conditions":5462,"interventions":5463},"NCT00783276","An fMRI Study of SYN115 in Cocaine Dependent Subjects",[84],"2008-10",[2485],[5453],{"trials":5465,"activeCount":97},[],{"trials":5467,"activeCount":97},[],{"trials":5469,"activeCount":97},[],{"trials":5471,"activeCount":97},[],{"trials":5473,"activeCount":97},[],{"intervention":5475,"totalTrials":93,"cells":5476},"MitoQ",{"EARLY_PHASE1":5477,"PHASE1":5486,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5478,"activeCount":97},[5479],{"nctId":5480,"briefTitle":5481,"status":228,"phases":5482,"primaryCompletion":5368,"completion":5368,"start":5483,"enrollment":477,"conditions":5484,"interventions":5485},"NCT05605548","Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)",[84],"2023-02-16",[5362],[5475],{"trials":5487,"activeCount":97},[],{"trials":5489,"activeCount":97},[],{"trials":5491,"activeCount":97},[],{"trials":5493,"activeCount":97},[],{"trials":5495,"activeCount":97},[],{"intervention":5497,"totalTrials":93,"cells":5498},"4- [F-18] fluoropaclitaxel",{"EARLY_PHASE1":5499,"PHASE1":5508,"PHASE2":5510,"PHASE3":5512,"PHASE4":5514,"NA":5516},{"trials":5500,"activeCount":97},[5501],{"nctId":5502,"briefTitle":5503,"status":179,"phases":5504,"primaryCompletion":5505,"completion":5505,"start":2628,"enrollment":2813,"conditions":5506,"interventions":5507},"NCT00572598","Pilot Study of 18F Fluoropaclitaxel (FPAC)",[84],"2008-03",[18],[5497],{"trials":5509,"activeCount":97},[],{"trials":5511,"activeCount":97},[],{"trials":5513,"activeCount":97},[],{"trials":5515,"activeCount":97},[],{"trials":5517,"activeCount":97},[],{"intervention":5373,"totalTrials":93,"cells":5519},{"EARLY_PHASE1":5520,"PHASE1":5526,"PHASE2":5528,"PHASE3":5530,"PHASE4":5532,"NA":5534},{"trials":5521,"activeCount":97},[5522],{"nctId":5365,"briefTitle":5366,"status":179,"phases":5523,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":5370,"conditions":5524,"interventions":5525},[84],[3923],[5351,5373],{"trials":5527,"activeCount":97},[],{"trials":5529,"activeCount":97},[],{"trials":5531,"activeCount":97},[],{"trials":5533,"activeCount":97},[],{"trials":5535,"activeCount":97},[],{"intervention":5537,"totalTrials":93,"cells":5538},"Lapatinib",{"EARLY_PHASE1":5539,"PHASE1":5549,"PHASE2":5551,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5540,"activeCount":97},[5541],{"nctId":5542,"briefTitle":5543,"status":228,"phases":5544,"primaryCompletion":4206,"completion":4389,"start":5545,"enrollment":2813,"conditions":5546,"interventions":5548},"NCT01427322","Randomized RT +\u002F- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease",[84],"2011-09",[5547],"Epithelial Cancer",[5537],{"trials":5550,"activeCount":97},[],{"trials":5552,"activeCount":97},[],{"trials":5554,"activeCount":97},[],{"trials":5556,"activeCount":97},[],{"trials":5558,"activeCount":97},[],{"intervention":5560,"totalTrials":93,"cells":5561},"non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies",{"EARLY_PHASE1":5562,"PHASE1":5574,"PHASE2":5576,"PHASE3":5578,"PHASE4":5580,"NA":5582},{"trials":5563,"activeCount":97},[5564],{"nctId":5565,"briefTitle":5566,"status":179,"phases":5567,"primaryCompletion":5568,"completion":5568,"start":5569,"enrollment":359,"conditions":5570,"interventions":5572},"NCT05557812","A Clinical Trial Comparing FS With ZOE and Non-eugenol Based Materials in Primary Teeth Pulpotomies",[84],"2025-02-01","2023-02-02",[5571],"Pulpitis",[5560,5573],"eugenol based zinc oxide and Ferric Sulfate",{"trials":5575,"activeCount":97},[],{"trials":5577,"activeCount":97},[],{"trials":5579,"activeCount":97},[],{"trials":5581,"activeCount":97},[],{"trials":5583,"activeCount":97},[],{"intervention":5573,"totalTrials":93,"cells":5585},{"EARLY_PHASE1":5586,"PHASE1":5592,"PHASE2":5594,"PHASE3":5596,"PHASE4":5598,"NA":5600},{"trials":5587,"activeCount":97},[5588],{"nctId":5565,"briefTitle":5566,"status":179,"phases":5589,"primaryCompletion":5568,"completion":5568,"start":5569,"enrollment":359,"conditions":5590,"interventions":5591},[84],[5571],[5560,5573],{"trials":5593,"activeCount":97},[],{"trials":5595,"activeCount":97},[],{"trials":5597,"activeCount":97},[],{"trials":5599,"activeCount":97},[],{"trials":5601,"activeCount":97},[],{"intervention":5603,"totalTrials":93,"cells":5604},"Direct acting Anti-Viral Therapy using Epclusa or Zepatier",{"EARLY_PHASE1":5605,"PHASE1":5617,"PHASE2":5619,"PHASE3":5621,"PHASE4":5623,"NA":5625},{"trials":5606,"activeCount":97},[5607],{"nctId":5608,"briefTitle":5609,"status":179,"phases":5610,"primaryCompletion":5611,"completion":5611,"start":5612,"enrollment":5613,"conditions":5614,"interventions":5616},"NCT03249194","Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients",[84],"2020-03-15","2017-08-17",25,[5615,2374],"Kidney Transplant",[5603],{"trials":5618,"activeCount":97},[],{"trials":5620,"activeCount":97},[],{"trials":5622,"activeCount":97},[],{"trials":5624,"activeCount":97},[],{"trials":5626,"activeCount":97},[],{"intervention":5628,"totalTrials":93,"cells":5629},"Vorinostat Oral Capsule Group 1",{"EARLY_PHASE1":5630,"PHASE1":5642,"PHASE2":5644,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5631,"activeCount":97},[5632],{"nctId":5633,"briefTitle":5634,"status":207,"phases":5635,"primaryCompletion":5636,"completion":5636,"start":5637,"enrollment":97,"conditions":5638,"interventions":5640},"NCT03263533","HDAC Inhibitor Augmentation to Clozapine",[84],"2019-02","2017-04",[5639],"Schizophrenia",[5628,5641],"Vorinostat Oral Capsule Group 2",{"trials":5643,"activeCount":97},[],{"trials":5645,"activeCount":97},[],{"trials":5647,"activeCount":97},[],{"trials":5649,"activeCount":97},[],{"trials":5651,"activeCount":97},[],{"intervention":5641,"totalTrials":93,"cells":5653},{"EARLY_PHASE1":5654,"PHASE1":5660,"PHASE2":5662,"PHASE3":5664,"PHASE4":5666,"NA":5668},{"trials":5655,"activeCount":97},[5656],{"nctId":5633,"briefTitle":5634,"status":207,"phases":5657,"primaryCompletion":5636,"completion":5636,"start":5637,"enrollment":97,"conditions":5658,"interventions":5659},[84],[5639],[5628,5641],{"trials":5661,"activeCount":97},[],{"trials":5663,"activeCount":97},[],{"trials":5665,"activeCount":97},[],{"trials":5667,"activeCount":97},[],{"trials":5669,"activeCount":97},[],{"intervention":5671,"totalTrials":319,"cells":5672},"Lorazepam",{"EARLY_PHASE1":5673,"PHASE1":5675,"PHASE2":5677,"PHASE3":5679,"PHASE4":5681,"NA":5693},{"trials":5674,"activeCount":97},[],{"trials":5676,"activeCount":97},[],{"trials":5678,"activeCount":97},[],{"trials":5680,"activeCount":97},[],{"trials":5682,"activeCount":97},[5683],{"nctId":5684,"briefTitle":5685,"status":179,"phases":5686,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5692},"NCT00249366","Treatment of Alcohol Withdrawal in Hospital Patients",[88],"2003-05","2001-04",183,[5691],"Alcohol Withdrawal Syndrome",[5671,5671],{"trials":5694,"activeCount":97},[5695],{"nctId":5696,"briefTitle":5697,"status":179,"phases":5698,"primaryCompletion":5699,"completion":5700,"start":5701,"enrollment":222,"conditions":5702,"interventions":5703},"NCT01204255","Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers",[89],"2011-04-18","2011-05-17","2010-11-15",[2876],[5704,5705,5706],"lorazepam","diphenhydramine hydrochloride","haloperidol",{"intervention":2005,"totalTrials":319,"cells":5708},{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5723},{"trials":5710,"activeCount":97},[],{"trials":5712,"activeCount":97},[],{"trials":5714,"activeCount":97},[],{"trials":5716,"activeCount":97},[],{"trials":5718,"activeCount":97},[5719],{"nctId":1997,"briefTitle":1998,"status":207,"phases":5720,"primaryCompletion":2000,"completion":2000,"start":2000,"enrollment":97,"conditions":5721,"interventions":5722},[88],[2002,2003],[2005,1984],{"trials":5724,"activeCount":97},[5725],{"nctId":5726,"briefTitle":5727,"status":179,"phases":5728,"primaryCompletion":5729,"completion":5730,"start":5731,"enrollment":1345,"conditions":5732,"interventions":5735},"NCT03486106","Music Distraction and Its Influence on Anesthetic Requirements During Elective Knee Surgery",[89],"2019-07-12","2019-07-15","2018-07-13",[5733,5734],"Anesthesia; Functional","Surgery",[2005],{"intervention":5737,"totalTrials":93,"cells":5738},"Gene Expression Analysis",{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5743,"PHASE3":5745,"PHASE4":5747,"NA":5749},{"trials":5740,"activeCount":97},[],{"trials":5742,"activeCount":97},[],{"trials":5744,"activeCount":97},[],{"trials":5746,"activeCount":97},[],{"trials":5748,"activeCount":97},[],{"trials":5750,"activeCount":97},[5751],{"nctId":5752,"briefTitle":5753,"status":179,"phases":5754,"primaryCompletion":302,"completion":4895,"start":3090,"enrollment":1280,"conditions":5755,"interventions":5758},"NCT01293032","Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer",[89],[5756,5757,340,341,342,343,344],"Ductal Breast Carcinoma in Situ","Lobular Breast Carcinoma in Situ",[5737,5759,5760,5761],"Systemic Chemotherapy","Tamoxifen Citrate","Aromatase Inhibition Therapy",{"intervention":5759,"totalTrials":93,"cells":5763},{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5765,"activeCount":97},[],{"trials":5767,"activeCount":97},[],{"trials":5769,"activeCount":97},[],{"trials":5771,"activeCount":97},[],{"trials":5773,"activeCount":97},[],{"trials":5775,"activeCount":97},[5776],{"nctId":5752,"briefTitle":5753,"status":179,"phases":5777,"primaryCompletion":302,"completion":4895,"start":3090,"enrollment":1280,"conditions":5778,"interventions":5779},[89],[5756,5757,340,341,342,343,344],[5737,5759,5760,5761],{"intervention":5760,"totalTrials":93,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5786,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5783,"activeCount":97},[],{"trials":5785,"activeCount":97},[],{"trials":5787,"activeCount":97},[],{"trials":5789,"activeCount":97},[],{"trials":5791,"activeCount":97},[],{"trials":5793,"activeCount":97},[5794],{"nctId":5752,"briefTitle":5753,"status":179,"phases":5795,"primaryCompletion":302,"completion":4895,"start":3090,"enrollment":1280,"conditions":5796,"interventions":5797},[89],[5756,5757,340,341,342,343,344],[5737,5759,5760,5761],{"intervention":5761,"totalTrials":93,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5804,"PHASE3":5806,"PHASE4":5808,"NA":5810},{"trials":5801,"activeCount":97},[],{"trials":5803,"activeCount":97},[],{"trials":5805,"activeCount":97},[],{"trials":5807,"activeCount":97},[],{"trials":5809,"activeCount":97},[],{"trials":5811,"activeCount":97},[5812],{"nctId":5752,"briefTitle":5753,"status":179,"phases":5813,"primaryCompletion":302,"completion":4895,"start":3090,"enrollment":1280,"conditions":5814,"interventions":5815},[89],[5756,5757,340,341,342,343,344],[5737,5759,5760,5761],{"intervention":5817,"totalTrials":93,"cells":5818},"aminoglycoside",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5820,"activeCount":97},[],{"trials":5822,"activeCount":97},[],{"trials":5824,"activeCount":97},[],{"trials":5826,"activeCount":97},[],{"trials":5828,"activeCount":97},[],{"trials":5830,"activeCount":97},[5831],{"nctId":5832,"briefTitle":5833,"status":179,"phases":5834,"primaryCompletion":5835,"completion":5835,"start":5836,"enrollment":5837,"conditions":5838,"interventions":5841},"NCT00308906","Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children",[],"2010-12","2006-06",166,[5839,5840],"Infection","Renal Dysfunction",[5817],{"intervention":5843,"totalTrials":93,"cells":5844},"diazoxide",{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5851,"PHASE4":5853,"NA":5855},{"trials":5846,"activeCount":97},[],{"trials":5848,"activeCount":97},[],{"trials":5850,"activeCount":97},[],{"trials":5852,"activeCount":97},[],{"trials":5854,"activeCount":97},[],{"trials":5856,"activeCount":97},[5857],{"nctId":5858,"briefTitle":5859,"status":179,"phases":5860,"primaryCompletion":5861,"completion":5861,"start":1805,"enrollment":756,"conditions":5862,"interventions":5863},"NCT00683774","Insulin and Polycystic Ovary Syndrome",[89],"2008-12",[1322],[5843],{"intervention":5865,"totalTrials":93,"cells":5866},"pioglitazone",{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5871,"PHASE3":5873,"PHASE4":5875,"NA":5877},{"trials":5868,"activeCount":97},[],{"trials":5870,"activeCount":97},[],{"trials":5872,"activeCount":97},[],{"trials":5874,"activeCount":97},[],{"trials":5876,"activeCount":97},[],{"trials":5878,"activeCount":97},[5879],{"nctId":5880,"briefTitle":5881,"status":228,"phases":5882,"primaryCompletion":5883,"completion":220,"start":5884,"enrollment":5270,"conditions":5885,"interventions":5886},"NCT00868140","Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)",[89],"2011-06","2009-02",[1807],[5865],{"intervention":5888,"totalTrials":93,"cells":5889},"Dextromethorphan",{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5894,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5891,"activeCount":97},[],{"trials":5893,"activeCount":97},[],{"trials":5895,"activeCount":97},[],{"trials":5897,"activeCount":97},[],{"trials":5899,"activeCount":97},[],{"trials":5901,"activeCount":97},[5902],{"nctId":5903,"briefTitle":5904,"status":179,"phases":5905,"primaryCompletion":5906,"completion":5906,"start":5907,"enrollment":5908,"conditions":5909,"interventions":5911},"NCT00310323","Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea",[89],"2006-02","2003-01",69,[5910],"Sleep Apnea",[5888,5912],"Caffeine",{"intervention":5912,"totalTrials":93,"cells":5914},{"EARLY_PHASE1":5915,"PHASE1":5917,"PHASE2":5919,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5916,"activeCount":97},[],{"trials":5918,"activeCount":97},[],{"trials":5920,"activeCount":97},[],{"trials":5922,"activeCount":97},[],{"trials":5924,"activeCount":97},[],{"trials":5926,"activeCount":97},[5927],{"nctId":5903,"briefTitle":5904,"status":179,"phases":5928,"primaryCompletion":5906,"completion":5906,"start":5907,"enrollment":5908,"conditions":5929,"interventions":5930},[89],[5910],[5888,5912],{"intervention":5932,"totalTrials":93,"cells":5933},"Azacitidine",{"EARLY_PHASE1":5934,"PHASE1":5936,"PHASE2":5938,"PHASE3":5940,"PHASE4":5942,"NA":5944},{"trials":5935,"activeCount":97},[],{"trials":5937,"activeCount":97},[],{"trials":5939,"activeCount":97},[],{"trials":5941,"activeCount":97},[],{"trials":5943,"activeCount":97},[],{"trials":5945,"activeCount":97},[5946],{"nctId":5947,"briefTitle":5948,"status":179,"phases":5949,"primaryCompletion":5950,"completion":4896,"start":1804,"enrollment":252,"conditions":5951,"interventions":5952},"NCT01050790","Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma",[89],"2014-08",[2150],[5932],{"intervention":5954,"totalTrials":93,"cells":5955},"Flutamide",{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5957,"activeCount":97},[],{"trials":5959,"activeCount":97},[],{"trials":5961,"activeCount":97},[],{"trials":5963,"activeCount":97},[],{"trials":5965,"activeCount":97},[],{"trials":5967,"activeCount":97},[5968],{"nctId":5969,"briefTitle":5970,"status":228,"phases":5971,"primaryCompletion":314,"completion":314,"start":4113,"enrollment":5370,"conditions":5972,"interventions":5973},"NCT00729560","Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome",[89],[1807],[5954],{"intervention":5975,"totalTrials":93,"cells":5976},"nicotine transdermal system",{"EARLY_PHASE1":5977,"PHASE1":5979,"PHASE2":5981,"PHASE3":5983,"PHASE4":5985,"NA":5987},{"trials":5978,"activeCount":97},[],{"trials":5980,"activeCount":97},[],{"trials":5982,"activeCount":97},[],{"trials":5984,"activeCount":97},[],{"trials":5986,"activeCount":97},[],{"trials":5988,"activeCount":97},[5989],{"nctId":5990,"briefTitle":5991,"status":179,"phases":5992,"primaryCompletion":5505,"completion":5505,"start":5993,"enrollment":783,"conditions":5994,"interventions":5997},"NCT00390559","Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3",[89],"2005-10",[5995,5996],"Drug Addiction","Smoking Cessation",[5975,5998],"Nicotine transdermal system",{"intervention":6000,"totalTrials":93,"cells":6001},"NuvaRing",{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6006,"PHASE3":6008,"PHASE4":6010,"NA":6012},{"trials":6003,"activeCount":97},[],{"trials":6005,"activeCount":97},[],{"trials":6007,"activeCount":97},[],{"trials":6009,"activeCount":97},[],{"trials":6011,"activeCount":97},[],{"trials":6013,"activeCount":97},[6014],{"nctId":6015,"briefTitle":6016,"status":228,"phases":6017,"primaryCompletion":2213,"completion":242,"start":6018,"enrollment":6019,"conditions":6020,"interventions":6022},"NCT00369967","Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents",[89],"2007-02",48,[6021],"Contraception Desired",[6000],{"intervention":6024,"totalTrials":93,"cells":6025},"Peginterferon Alpha-2a",{"EARLY_PHASE1":6026,"PHASE1":6028,"PHASE2":6030,"PHASE3":6032,"PHASE4":6034,"NA":6036},{"trials":6027,"activeCount":97},[],{"trials":6029,"activeCount":97},[],{"trials":6031,"activeCount":97},[],{"trials":6033,"activeCount":97},[],{"trials":6035,"activeCount":97},[],{"trials":6037,"activeCount":97},[6038],{"nctId":6039,"briefTitle":6040,"status":179,"phases":6041,"primaryCompletion":1411,"completion":1411,"start":1805,"enrollment":285,"conditions":6042,"interventions":6044},"NCT00252642","Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C",[89],[2374,786,6043],"Fibrosis",[6024],{"intervention":6046,"totalTrials":93,"cells":6047},"Proton pump inhibitor",{"EARLY_PHASE1":6048,"PHASE1":6050,"PHASE2":6052,"PHASE3":6054,"PHASE4":6056,"NA":6058},{"trials":6049,"activeCount":97},[],{"trials":6051,"activeCount":97},[],{"trials":6053,"activeCount":97},[],{"trials":6055,"activeCount":97},[],{"trials":6057,"activeCount":97},[],{"trials":6059,"activeCount":97},[6060],{"nctId":6061,"briefTitle":6062,"status":207,"phases":6063,"primaryCompletion":6064,"enrollment":97,"conditions":6065,"interventions":6069},"NCT02039869","Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)",[89],"2015-12",[6066,6067,6068],"Gastroesophageal Reflux Disease","Non Erosive Reflux Disease","Dyspepsia",[6046,6070],"Sucralfate",{"intervention":6070,"totalTrials":93,"cells":6072},{"EARLY_PHASE1":6073,"PHASE1":6075,"PHASE2":6077,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6074,"activeCount":97},[],{"trials":6076,"activeCount":97},[],{"trials":6078,"activeCount":97},[],{"trials":6080,"activeCount":97},[],{"trials":6082,"activeCount":97},[],{"trials":6084,"activeCount":97},[6085],{"nctId":6061,"briefTitle":6062,"status":207,"phases":6086,"primaryCompletion":6064,"enrollment":97,"conditions":6087,"interventions":6088},[89],[6066,6067,6068],[6046,6070],{"intervention":6090,"totalTrials":93,"cells":6091},"miRNA sampling",{"EARLY_PHASE1":6092,"PHASE1":6094,"PHASE2":6096,"PHASE3":6098,"PHASE4":6100,"NA":6102},{"trials":6093,"activeCount":97},[],{"trials":6095,"activeCount":97},[],{"trials":6097,"activeCount":97},[],{"trials":6099,"activeCount":97},[],{"trials":6101,"activeCount":97},[],{"trials":6103,"activeCount":97},[6104],{"nctId":6105,"briefTitle":6106,"status":3760,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":6110,"conditions":6111,"interventions":6113},"NCT03905434","Identification of microRNAs Involved in Cerebral Collateral Regulation",[],"2027-12-01","2018-08-14",45,[6112],"Cerebrovascular Disorders",[6090],{"intervention":6115,"totalTrials":93,"cells":6116},"Metformin 500 mg",{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6127},{"trials":6118,"activeCount":97},[],{"trials":6120,"activeCount":97},[],{"trials":6122,"activeCount":97},[],{"trials":6124,"activeCount":97},[],{"trials":6126,"activeCount":97},[],{"trials":6128,"activeCount":97},[6129],{"nctId":6130,"briefTitle":6131,"status":179,"phases":6132,"primaryCompletion":6133,"completion":384,"start":4113,"enrollment":6134,"conditions":6135,"interventions":6136},"NCT00703508","Pharmacogenetics of Metformin Action in PCOS",[89],"2013-09",55,[1807],[6115],{"intervention":6138,"totalTrials":93,"cells":6139},"Erythromycin",{"EARLY_PHASE1":6140,"PHASE1":6142,"PHASE2":6144,"PHASE3":6146,"PHASE4":6148,"NA":6150},{"trials":6141,"activeCount":97},[],{"trials":6143,"activeCount":97},[],{"trials":6145,"activeCount":97},[],{"trials":6147,"activeCount":97},[],{"trials":6149,"activeCount":97},[],{"trials":6151,"activeCount":97},[6152],{"nctId":6153,"briefTitle":6154,"status":179,"phases":6155,"primaryCompletion":6156,"completion":6156,"start":1882,"enrollment":881,"conditions":6157,"interventions":6159},"NCT02005029","Erythromycin in Parkinson's Disease",[89],"2015-06",[5272,6158],"Levodopa",[6138],{"intervention":6161,"totalTrials":93,"cells":6162},"ABH gel",{"EARLY_PHASE1":6163,"PHASE1":6165,"PHASE2":6167,"PHASE3":6169,"PHASE4":6171,"NA":6173},{"trials":6164,"activeCount":97},[],{"trials":6166,"activeCount":97},[],{"trials":6168,"activeCount":97},[],{"trials":6170,"activeCount":97},[],{"trials":6172,"activeCount":97},[],{"trials":6174,"activeCount":97},[6175],{"nctId":6176,"briefTitle":6177,"status":179,"phases":6178,"primaryCompletion":6179,"completion":1881,"start":6180,"enrollment":16,"conditions":6181,"interventions":6184},"NCT01556932","Randomized Trial of the Effectiveness of Topical \"ABH Gel\" vs. Placebo in Cancer Patients With Nausea",[89],"2013-05","2012-03",[6182,6183],"Nausea","Vomiting",[6161],{"intervention":5705,"totalTrials":93,"cells":6186},{"EARLY_PHASE1":6187,"PHASE1":6189,"PHASE2":6191,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6188,"activeCount":97},[],{"trials":6190,"activeCount":97},[],{"trials":6192,"activeCount":97},[],{"trials":6194,"activeCount":97},[],{"trials":6196,"activeCount":97},[],{"trials":6198,"activeCount":97},[6199],{"nctId":5696,"briefTitle":5697,"status":179,"phases":6200,"primaryCompletion":5699,"completion":5700,"start":5701,"enrollment":222,"conditions":6201,"interventions":6202},[89],[2876],[5704,5705,5706],{"intervention":5706,"totalTrials":93,"cells":6204},{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6211,"PHASE4":6213,"NA":6215},{"trials":6206,"activeCount":97},[],{"trials":6208,"activeCount":97},[],{"trials":6210,"activeCount":97},[],{"trials":6212,"activeCount":97},[],{"trials":6214,"activeCount":97},[],{"trials":6216,"activeCount":97},[6217],{"nctId":5696,"briefTitle":5697,"status":179,"phases":6218,"primaryCompletion":5699,"completion":5700,"start":5701,"enrollment":222,"conditions":6219,"interventions":6220},[89],[2876],[5704,5705,5706],{"intervention":6222,"totalTrials":93,"cells":6223},"Divalproex Sodium Extended-Release",{"EARLY_PHASE1":6224,"PHASE1":6226,"PHASE2":6228,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6225,"activeCount":97},[],{"trials":6227,"activeCount":97},[],{"trials":6229,"activeCount":97},[],{"trials":6231,"activeCount":97},[],{"trials":6233,"activeCount":97},[],{"trials":6235,"activeCount":97},[6236],{"nctId":6237,"briefTitle":6238,"status":179,"phases":6239,"primaryCompletion":6240,"completion":6240,"start":6241,"enrollment":170,"conditions":6242,"interventions":6246},"NCT00318929","Tolerability and Efficacy of Depakote-extended Release in the Elderly",[89],"2008-01","2006-04",[6243,6244,6245],"Elderly","Epilepsy","Seizures",[6222]]